Official Title: Geniculate Artery Embolization for Treatment of Knee Osteoarthritis
NCT Number : [STUDY_ID_REMOVED] 
Study Number: 19-[ZIP_CODE]
Document Type:   Study Protocol and Statistical Analysis Plan 
Date of the 
Document:  May 6, 2025
Page i 
CONFIDENTIAL
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_625659]: 12 February 2020
Geniculate Artery Embolization for Treatment of Knee Osteoarthritis
Principal Investigator: [INVESTIGATOR_772006], M.D.
Clinical Assistant Professor, Vascular and Interventional Radiology 
Director, VIR Research Program 
Department of Radiology, NYU Langone Health 
[ADDRESS_1059926], 2ndFloor, [LOCATION_001], NY, [ZIP_CODE]
Email: [EMAIL_14729]  
Phone: [PHONE_16095]
Additional Investigators:
Jonathan Samuels, M.D.
Associate Professor, 
Department of Internal Medicine, NYU Langone Health 
[ADDRESS_1059927], 4th Floor
[LOCATION_001], NY [ZIP_CODE]
Email: [EMAIL_14730]  
Phone: [PHONE_2192] 
Erin F. Alaia, M.D. 
Assistant [CONTACT_29190] of Radiology, NYU Langone Health 
[ADDRESS_1059928], 2nd Floor
Email: [EMAIL_14731]  
Phone: [PHONE_16096]
NYULMC Study Number: s19-[ZIP_CODE]
Funding Sponsor: Department of Radiology 
IND/IDE Number: G190316
Regulatory Sponsor: Bedros Taslakian, M.D.
Department of Radiology, NYU Langone Health 
Director, VIR Research Program 
[ADDRESS_1059929], 2ndFloor, [LOCATION_001], NY, [ZIP_CODE]
Email: [EMAIL_14729]; Phone: [PHONE_16097]
Study Product: Embozene™ Color-Advanced Microspheres
Study Product Provider: Varian Medical Systems, Inc
ClinicalTrials.gov 
Number                [STUDY_ID_REMOVED]
Initial version: 04/16/2020
Amended: 19 Apr 2021
Amended: 31 January 2022
Amended:           07/06/2022
Amended:           02/08/2023
Amended:           06.25.2024
Amended 03.16.2025
Study number: s19-[ZIP_CODE] Page ii
Version: 06.25.2024  
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_553748]: 12 February 2020Statement of Compliance 
This study will be conducted in accordance with the Code of Federal Regulations on the Protection of 
Human Subjects (45 CFR Part 46), 21 CFR Parts 50, 56, 312, and 812 as applicable, any other applicable 
US government research regulations, and institutional research policies and procedures. The International 
Conference on Harmonisation (“ICH”) Guideline for Good Clinical Practice (“GCP”) (sometimes referred to 
as “ICH-GCP” or “E6”) will be applied only to the extent that it is compatible with FDA and DHHS regulations. 
The Principal Investigator [INVESTIGATOR_7433], or changes to the protocol will take place 
without prior agreement from the sponsor and documented approval from the Institutional Review Board 
(IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants. All personnel 
involved in the conduct of this study have completed Human Subjects Protection Training. 
 
Study number: s19-[ZIP_CODE] Page iii
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_553748]: [ADDRESS_1059930] OF ABBREVIATIONS......................................................................................................................... VI
PROTOCOL SUMMARY .............................................................................................................................. 8
SCHEMATIC OF STUDY DESIGN.............................................................................................................10
1 KEY ROLES ....................................................................................................................................... 14
2 INTRODUCTION, BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE ..................... 15
2.1 B ACKGROUND INFORMATION AND RELEVANT LITERATURE ..............................................................15
2.2 NAME [CONTACT_33914]............................................................ 16
2.2.1 Preclinical Data...................................................................................................................... 17
2.2.2 Clinical Data to Date..............................................................................................................17
2.3 RATIONALE .................................................................................................................................. 18
2.4 POTENTIAL RISKS &BENEFITS ...................................................................................................... 19
2.4.1 Known Potential Risks ........................................................................................................... 19
2.4.2 Known Potential Benefits ......................................................................................................21
3 OBJECTIVES AND PURPOSE......................................................................................................... 21
3.1 PRIMARY OBJECTIVE  .................................................................................................................... 21
3.2 SECONDARY OBJECTIVES (IF APPLICABLE ) .................................................................................... 22
4 STUDY DESIGN AND ENDPOINTS .................................................................................................. 22
4.1 DESCRIPTION OF STUDY DESIGN.................................................................................................. 22
4.2 STUDY ENDPOINTS ....................................................................................................................... 23
4.2.1 Primary Study Endpoints ....................................................................................................... 23
4.2.2 Secondary Study Endpoints Analysis ................................................................................... 23
5 STUDY ENROLLMENT AND WITHDRAWAL .................................................................................. 24
5.1 INCLUSION CRITERIA.................................................................................................................... 24
5.2 EXCLUSION CRITERIA ................................................................................................................... 24
5.3 VULNERABLE SUBJECTS ............................................................................................................... 25
5.4 STRATEGIES FOR RECRUITMENT AND RETENTION  .......................................................................... 25
5.4.1 Use of DataCore/Epic Information for Recruitment Purposes .............................................. 25
5.5 DURATION OF STUDY PARTICIPATION ............................................................................................ 26
5.6 T OTAL NUMBER OF PARTICIPANTS AND SITES................................................................................26
5.7 PARTICIPANT WITHDRAWAL OR TERMINATION ................................................................................ 26
5.7.1 Reasons for Withdrawal or Termination ................................................................................ 26
5.7.2 Handling of Participant Withdrawals or Termination ............................................................. 27
5.8 PREMATURE TERMINATION OR SUSPENSION OF STUDY .................................................................. 27
6 STUDY AGENT (STUDY DEVICE) AND/OR PROCEDURAL INTERVENTION .............................. [ADDRESS_1059931] Storage and Stability ................................................................................................ 28
6.1.4 Preparation ............................................................................................................................ 28
6.1.5 Dosing and Administration .................................................................................................... 28
6.1.6 Route of Administration ......................................................................................................... 28
6.1.7 Duration of Therapy ............................................................................................................... 28
6.1.8 Device Specific Considerations ............................................................................................. 29
6.2 STUDY PROCEDURAL INTERVENTION (S)DESCRIPTION ................................................................... 29
6.2.1 Administration of Procedural Intervention ............................... Error! Bookmark not defined.
Study number: s19-[ZIP_CODE] Page iv
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_553748]: 12 February [ZIP_CODE].2.2 Procedures for Training of Clinicians on Procedural Intervention ......................................... 29
7 STUDY PROCEDURES AND SCHEDULE.......................................................................................30
7.1 STUDY PROCEDURES /EVALUATIONS ............................................................................................. [ADDRESS_1059932] of Care Study Procedures.....................................................................................30
7.2 LABORATORY PROCEDURES /EVALUATIONS ................................................................................... 31
7.2.1 Laboratory Evaluations .......................................................................................................... 31
7.3 S TUDY SCHEDULE ........................................................................................................................32
7.3.1 Screening .............................................................................................................................. 32
7.3.2 Enrollment/Baseline (Visit 2, Day -29 to -1)- In interventional radiology clinic ...................... 33
7.3.3 Interventional visit (visit 3, Day 0)..........................................................................................33
7.3.4 Follow-up Visits ..................................................................................................................... 33
7.3.5 Withdrawal/Early Termination Visit........................................................................................ 34
7.3.6 Unscheduled Visit..................................................................................................................34
7.4 CONCOMITANT MEDICATIONS ,TREATMENTS ,AND PROCEDURES  .................................................... 35
7.5 RESCUE MEDICATIONS ,TREATMENTS ,AND PROCEDURES ............................................................. 35
7.6 P ARTICIPANT ACCESS TO STUDY AGENT AT STUDY CLOSURE........................................................35
8 ASSESSMENT OF SAFETY ............................................................................................................. 35
8.1 SPECIFICATION OF SAFETY PARAMETERS ...................................................................................... 35
8.1.1 Definition of Adverse Events (AE) ......................................................................................... 36
8.1.2 Definition of Serious Adverse Events (SAE) ......................................................................... 36
8.1.3 Definition of Unanticipated Problems (UP) ............................................................................ 36
8.2 CLASSIFICATION OF AN ADVERSE EVENT ....................................................................................... 37
8.2.1 Severity of Event ................................................................................................................... 37
8.2.2 Relationship to Study Device ................................................................................................ 37
8.2.3 Expectedness ........................................................................................................................ 38
8.3 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW-UP.................................... 38
8.4 REPORTING PROCEDURES –NOTIFYING THE IRB .......................................................................... 39
8.4.1 Adverse Event Reporting ...................................................................................................... 39
8.4.2 Serious Adverse Event Reporting ......................................................................................... 39
8.4.3 Unanticipated Problem Reporting ......................................................................................... 39
8.4.4 Reporting of Pregnancy ......................................................................................................... 40
8.5 REPORTING PROCEDURES –NOTIFYING THE STUDY SPONSOR...................................................... 40
8.6 REPORTING PROCEDURES –NOTIFYING THE FDA......................................................................... 40
8.7 STUDY HALTING RULES................................................................ ERROR!BOOKMARK NOT DEFINED .
8.8 S AFETY OVERSIGHT .....................................................................................................................41
9 CLINICAL MONITORING .................................................................................................................. 42
10 STATISTICAL CONSIDERATIONS .................................................................................................. 42
10.1 S TATISTICAL AND ANALYTICAL PLANS (SAP) ................................................................................. 42
10.2 S TATISTICAL HYPOTHESES  ........................................................................................................... 42
10.3 A NALYSIS DATASETS .................................................................................................................... 42
10.4 D ESCRIPTION OF STATISTICAL METHODS...................................................................................... 43
10.4.1 General Approach ............................................................................................................. 43
10.4.2 Analysis of the Primary Endpoint(s) .................................................................................. 43
10.4.3 Analysis of the Secondary Endpoint(s) ............................................................................. 43
10.4.4 Safety Analyses ................................................................................................................ 43
10.5 S AMPLE SIZE............................................................................................................................... 43
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS ................................. 44
12 QUALITY ASSURANCE AND QUALITY CONTROL ....................................................................... 44
13 ETHICS/PROTECTION OF HUMAN SUBJECTS ............................................................................. [ADDRESS_1059933]  ..................................................................................................................... 45
Study number: s19-[ZIP_CODE] Page v
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_553748]: [ADDRESS_1059934]..................................................................................................... 45
13.3 I NFORMED CONSENT PROCESS....................................................................................................45
13.3.1 Consent/Assent and Other Informational Documents Provided to Participants ............... [ADDRESS_1059935] POLICY .................................................................................................. 49
18 REFERENCES ................................................................................................................................... 49
19 ATTACHMENTS ................................................................................................................................ 51
20 SCHEDULE OF EVENTS ....................................................... ERROR! BOOKMARK NOT DEFINED.
 
Study number: s19-[ZIP_CODE] Page vi
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_553748]: [ADDRESS_1059936] of Abbreviations 
AE Adverse Event/Adverse Experience
CFR Code of Federal Regulations 
CRF Case Report Form
CSOC Clinical Study Oversight Committee
CVA Cerebrovascular accident
DCC Data Coordinating Center
DHHS Department of Health and Human Services
DSMB Data and Safety Monitoring Board
DFU Direction for Use 
eCRF Electronic case report form
FFR Federal Financial Report
FWA Federal wide Assurance
GCP Good Clinical Practice
HIPAA Health Insurance Portability and Accountability Act
ICF Informed Consent Form
ICH International Conference on Harmonisation
IRB Institutional Review Board
ISM Independent Safety Monitor
MOP Manual of Procedures
MR Magnetic Resonance
N Number (typi[INVESTIGATOR_33891])
NIH National Institutes of Health
OHRP Office for Human Research Protections
OHSR Office of Human Subjects Research
OA Osteoarthritis 
PI [INVESTIGATOR_772007]/Serious Adverse Experience 
SOP Standard Operating Procedure 
TP Treating physician
Study number: s19-[ZIP_CODE] Page vii
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_553748]: 12 February 2020US [LOCATION_002]
UP Unanticipated problem 
VAS Visual analog scale 
WOMAC Western Ontario and McMaster Universities Osteoarthritis index
WOMRS  Whole-Organ Magnetic Resonance Imaging Score
Study number: s19-[ZIP_CODE]   Page 8
Version: 06.25.2024 
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February 2020Protocol Summary 
Title Genicular Artery Embolization for Treatment of  Knee Osteoarthritis (OA)
Short Title Geniculate Artery Embolization for Treatment of Knee Osteoarthritis 
Brief SummarySingle-arm, single-center, no sham or placebo, prospective pi[INVESTIGATOR_772008]. Eligible participants will receive 
geniculate artery embolization using Embozene™ Color-Advanced 
Microspheres. Patients will be followed up for a total of 12 months.  
ObjectivesPrimary objective:  to determine the effectiveness of genicular artery 
embolization in reducing knee pain at 3-months post intervention in patients 
with knee OA. This will be assessed by [CONTACT_772025] 50% reduction in Western Ontario and McMaster 
Universities Osteoarthritis index (WOMAC) pain score from pre-intervention 
baseline to follow-up visit at [ADDRESS_1059937]-intervention without an increase in 
baseline incidence of pain medication use or intra-articular injection. The 
WOMAC Score will be calculated from the Knee injury and Osteoarthritis 
Outcome Score (KOOS) score.  
Secondary objectives:   
- To evaluate the safety of genicular artery embolization 
- To determine whether transcatheter arterial embolization improves OA-
related knee symptoms and quality of life.  
Methodology Prospective, single-arm, single-center, no sham or placebo, pi[INVESTIGATOR_772009]: WOMAC pain score at 3-months post intervention. 
Secondary endpoints:
- Rate, type, causality, and severity of adverse events
- WOMAC pain score at 1-,12-, and > 12-months post intervention  
- Pain visual analog scale (VAS)  
- WOMAC knee stiffness and physical function scores at 1, 3, [ADDRESS_1059938] 31, 2024 will be invited to participate in longer follow up (18 months – 
48 months follow-up). 
Population40 patients, age 30-80, any gender, with grade 2,3, or 4 (in select subjects 
with no bone deformity) knee OA on the most recent knee radiographs 
obtained within 6 months of intervention 
Study number: s19-[ZIP_CODE]   Page 9
Version: 06.25.2024 
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February 2020Study Sites Single center: NYU Langone Health Hospi[INVESTIGATOR_772010] 40 patients will be required 
The study would accrue 50 patients to account for an attrition rate of 20%
Description of Study 
Agent/Procedure Embozene™ Color-Advanced Microspheres are spherical, tightly calibrated, 
biocompatible, non-resorbable, hydrogel microspheres coated with an 
inorganic perfluorinated polymer used for embolization.  
Key ProceduresTranscatheter arterial embolization of one or more genicular artery(ies) using 
Embozene™ Color-Advanced Microspheres
Statistical AnalysisThe primary objective is to assess the clinical success rate, which will be 
summarized in terms of the observed proportion of patients manifesting a 
positive response and a two-sided exact 95% confidence interval (CI) per the 
Blyth-Still-Casella method (reference). The treatment will be declared a 
success if the data support the conclusion that at least 75% of treated 
patients show a positive response. 
 
Study number: s19-[ZIP_CODE]   Page 10 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: [ADDRESS_1059939]-procedural blood samples  Baseline assessments
Document demographics and medical history, Perform physical exam 
Administer study questionnaires 
Obtain baseline knee x-ray and MRI (without contrast) 
Obtain baseline blood samples 
Safety follow-up 
Perform physical exam
Assess for short-term complications  
(clinic visit or phone/telemedicine) Study intervention 
Geniculate artery embolization 
3-month follow-up 
Perform physical exam
Administer study questionnaires 
Obtain post-procedural blood samples  
Obtain follow -up knee MRI without contrast
Final Assessments
12-month follow-up
Perform physical exam 
Administer study questionnaires 
Obtain post-procedural blood samples  
Study number: s19-[ZIP_CODE]   Page 11 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February 2020 
  
Study number: s19-[ZIP_CODE]   Page 12 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February 2020Schedule of Activities  
Visit # Visit 1* Visit2* Visit 3 Visit 4** Visit 5#Visit 6#Visit 7#Visit 8***
Visit Description Screening Baseline Intervention 1-day 
follow-up 1-month
follow-up 3-month
follow-up12-month
follow-up >12 
months 
Eligibility screen X
Informed consent X
Demographics X
Medical history X
Adverse Events X X X X X
Physical exam X X X X X X 
Medication History X X X X X
Pain VAS** X X X X X 
KOOS score X X X X X
EQ-5D-5L scale X X X X X 
Previous treatments X X X X X
Venous blood draws X##X##X X X X
Urine samples X X X X X
Knee MRI X1X3
Knee radiograph X2
Genicular artery 
embolizationX
1- If not previously available (i.e., recent knee MRI within 3 months of screening);  if MRI cannot be obtained on the 
same day due to subject preference and/or MRI scheduling related reasons, MRI can be performed anytime 
between the baseline visit and intervention visit   
2- If not previously available (i.e., recent knee radiograph within 6 months of screening). Can be performed on a 
separate day based on appointment availability or subject’s preference. 
3- Post-procedural MRI can be done on a separate day of visit [ADDRESS_1059940]’s 
preference as long as it’s performed within the timeframe of 3month +/- 10 days.   
 
 
* Visit [ADDRESS_1059941] preference. In that case, procedures listed in visit 2 will be performed after 
signing informed consent on the same day.   
 
** Visit 4 (1-day follow-up) dates range can be +3 days (phone call, telemedicine, or in-person IR clinic visit determined by 
[CONTACT_1130]’s preference and need for physical examination) 
*** Visit 8. Optional visit for participants who completed [ADDRESS_1059942] 31, 2024 (by [CONTACT_217092], voluntary, and 
after obtaining informed consent for this visit). This visit can be performed at any time interval within 18 months –48 months 4-
Study number: s19-[ZIP_CODE]   Page 13 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: [ADDRESS_1059943] procedure. This visit can be performed by [CONTACT_772026] a safe email and participants can email it back 
to research coordinator or PI [INVESTIGATOR_772011] a phone call performed by [CONTACT_164254], 
# 1, 3, 12-month follow-up dates range can be +/- 10 days 
## The pre-procedural blood work can be done on the day of the procedure prior to performing the procedure based on 
subject’s preference.  
Study number: s19-[ZIP_CODE]   Page 14 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February [ZIP_CODE] Key Roles 
-Principal Investigator (PI): Will be one of two interventional radiologists performing the procedure. Will be responsible for study integrity, 
data monitoring, data collection, statistical analysis, and manuscript writing.  
 
Bedros Taslakian, MD 
Clinical Assistant Professor of Radiology  
Director, Vascular and Interventional Radiology Research Program  
Department of Radiology, NYU Langone Heath  
[ADDRESS_1059944], 2ndFloor, [LOCATION_001], NY [ZIP_CODE]
Phone: [PHONE_16095] 
Email: [EMAIL_14729]  
 
 
- Co-PI: [CONTACT_15957]-investigator involved in recruiting patients and conducting the clinical assessment for knee osteoarthritis   
Jonathan Samuels, M.D 
Associate [CONTACT_3348] of Internal Medicine, NYU Langone Orthopedic Center 
[ADDRESS_1059945], 4th Floor 
[LOCATION_001], NY [ZIP_CODE] 
Email: [EMAIL_14730] 
 
- Co-PI: [CONTACT_15957]-investigator (musculoskeletal radiologist) conducting the imaging assessment  
Erin F. Alaia, MD 
Assistant [CONTACT_78052] of Radiology, NYU Langone Health  
[ADDRESS_1059946], 2nd Floor 
Email: [EMAIL_14731]  
Phone: [PHONE_16096] 
 
- Research Coordinator:  
 
- Biostatistician: Will be responsible for conduction statistical analysis   
James Babb, PhD 
Department of Radiology, NYU Langone Health 
[ADDRESS_1059947] 
[LOCATION_001], NY [ZIP_CODE] 
Phone: [PHONE_16098] 
Email: [EMAIL_14732]  
Study number: s19-[ZIP_CODE]   Page 15 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February [ZIP_CODE] Introduction, Background Information and Scientific Rationale 
2.1 Background Information and Relevant Literature
Knee OA is common and major cause of pain and disability. Its prevalence is rising due to an aging population and the high prevalence of obesity 
[1]. Radiographically confirmed symptomatic knee OA affects approximately 3.8% of people worldwide, and knee and hip OA ranked as the 11th
highest contributor to global disability [2]. Disabling symptoms of knee osteoarthritis are seen in an approximately 10 % of people over 55 years 
old [3]. Therefore, the prevalence and burden of knee OA presents a major challenge for health systems globally [2]. 
 
Knee OA is a complex, multifactorial disease with no known cure. Risk factors for knee OA include  
joint injury, bone and joint shape, muscle strength and mass, obesity, gender, metabolic factors, nutrition and vitamin factors, bone density, 
psychological health and occupation [4, 5]. Treatment seeks 
to manage symptoms, but adequate symptom control can be difficult to achieve [4-6]. Evidence-based treatment options for knee OA include intra-
articular corticosteroids, exercise, education, weight management, and oral medications such as acetaminophen and non-steroidal anti-
inflammatories for minor symptoms [7]. Total knee arthroplasty is generally reserved for those with severe joint disease, pain and functional 
limitations [8, 9]. On the other hand, moderate knee OA resistant to nonsurgical options, yet not severe enough to warrant joint replacement, does 
not have an optimal therapy. Therefore, there is still a need to develop an effective, minimally invasive and safe treatment for moderate OA of the 
knee. 
 
An in-depth understanding of OA pathophysiology is still emerging [1]. Recently, angiogenesis has been implicated in OA by [CONTACT_772027], inflammation and pain [10]. Angiogenesis is blood vessel overgrowth from pre-existing vasculature and is essential for growth, 
development and tissue repair [10]. However, in OA, angiogenesis increases in articular cartilage, synovium, meniscus, and osteophytes, and at 
the osteochondral junction [11-15]. Because angiogenesis is accompanied by [CONTACT_772028], perivascular nerve growth into normally 
aneural structures such as articular cartilage and meniscus is thought to contribute to OA pain through chemical and mechanical stimulation of 
newly formed nerves. Modifying angiogenesis and associated nerve growth is a potential treatment pathway to affect the pathogenesis and 
symptoms of OA [10]. Angiogenesis inhibitor treatment decreased pain-related behavior in animal models [11]. The mechanism of symptomatic 
relief is unclear but could include reduced synovitis, reduced periarticular innervation and nociception, and maintaining the integrity of the 
osteochondral junction [10, 11].  
 
A recent study by [CONTACT_772029] S et al evaluated the safety and effectiveness of GAE in patients with knee OS (grades 2, 3, 4). Knee OA severity was 
grade 2 in 18% of the patients, grade 3 in 43%, and grade 4 in 40%. Technical success was achieved in 100% of the subjects. The WOMAC total 
and VAS pain scores decreased by 61% and 67% at 12 months from a median baseline of 52 (of 96) and 8 (of 10), respectively. Twenty-seven 
 [32].  
The WOMAC questionnaire is a widely used, disease-specific measure for knee OA. It includes 24 questions on daily activities: five regarding 
pain, two regarding stiffness, and 17 regarding physical function; possible score ranges for each subset of items are as follows: pain, 0–20; 
stiffness, 0–8; and physical function, 0–68. For each question in each of the three categories (pain, stiffness, and physical function) patients 
receive the following points: 0 for no symptoms, 1 for mild, 2 for moderate, 3 for severe, and 4 for extreme symptoms. Higher scores on the 
WOMAC indicate worse pain, stiffness, and functional limitation [16]. 
 
The Whole-Organ Magnetic Resonance Imaging Score (WORMS) in patients with knee OA provides multi-feature, whole-organ assessment of the 
knee in OA using conventional magnetic resonance imaging (MRI), and shows high inter-observer agreement among trained readers [17]. Whole-
organ assessment could help discriminate different patterns of intra-articular involvement in OA; detect early, potentially preclinical, stages of OA; 
Study number: s19-[ZIP_CODE]   Page 16 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February 2020identify structural risk factors for developi[INVESTIGATOR_772012]; or increase scope and sensitivity to change for monitoring disease progression and 
treatment response in patients with established OA. It takes into account a variety of features that are currently believed to be relevant to the 
functional integrity of the knee and/or potentially involved in the pathophysiology of OA. It scores each of these features with a sufficient number of 
increments to allow detection of what are speculated to be clinically relevant changes. 
 
2.2 Name [CONTACT_772063] (device) in this trial is Embozene™ Color-Advanced Microspheres.  
 
Embozene™ Color-Advanced Microspheres are spherical, tightly calibrated, biocompatible, nonresorbable, hydrogel microspheres coated with an 
inorganic perfluorinated polymer (Polyzene™-F). The microspheres intended to occlude vasculature for the purpose of blocking blood flow to a 
target tissue. They are available in prefilled syringes in a range of sizes suitable for embolic therapy. The microspheres are compressible to enable 
smooth delivery through the indicated delivery catheter and color-coded by [CONTACT_772030]. In this trial, we intend to use 250 
  
 
Embozene™ Color-Advanced Microspheres are supplied in a [ADDRESS_1059948] suspended in a non-pyrogenic, sterile 
transport solution of physiological saline. The total volume of Embozene™ Color-Advanced Microspheres including transport solution is 
approximately 7 ml. Prefilled syringes of Embozene™ Color-Advanced Microspheres are packaged in a sterile, sealed tray with a peel-away lid. 
The label indicates the specific size of the microspheres contained in the syringe.  
 
Embozene™ Color-Advanced Microspheres are intended for embolization of arteriovenous malformations and hypervascular tumors, including 
uterine fibroids and hepatoma, and for embolization of prostatic 
arteries for symptomatic benign prostatic hyperplasia. This device is not intended for neurovascular use. The device is FDA approved for above 
indications (FDA approved for treatment of benign prostatic hyperplasia; FDA 510(K) # K180102; 510(k) premarket notification of intent to market 
the device FDA 510(k) # K141209) 
 
There are no known chemical interactions between Embozene™ Color-Advanced Microspheres and pharmaceuticals. 
 
Additionally, for labeling with Magnetic Resonance (MR) compatibility, the proposed Embozene™ Color-Advanced Microspheres were assessed 
and met requirements in the Guidance for Industry and Food and Drug Administration Staff Establishing Safety and Compatibility of Passive 
Implants in the MR Environment. Embozene™ Color-Advanced Microspheres are labeled MR safe in the device Direction for Use (DFU) 
[attachment 1] 
 
IDE for the purpose of this study was obtained from the FDA (IDE approval # G190316. Approval letter provided [attachment 2]. 
 
FDA documents of the device under investigation for approved indications and device DFU are attached to this IRB protocol [attachments 3,4].  
 
FDA reviewed the supplement of IDE application to expand study for significant risk device proposing the addition of 21 patients. FDA has 
determined sufficient data to support expansion of human clinical trial; this means there are no subject protection concerns that preclude 
expansion of the investigation. Approved to expand study. Limit 1 US institution and 50 US subjects. [attachment G190316-S003. 
Letter.EPEX.APPR] 
Study number: s19-[ZIP_CODE]   Page 17 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February 2020 
2.2.1 Preclinical Data 
Non-clinical tests performed on the Embozene Microspheres, reference device, provide reasonable 
assurance that the proposed device has been designed and tested to assure conformance to the 
requirements for its intended use. As the device received FDA approval for additional indications lately (prostate artery embolization), we believe 
that using the device for geniculate artery embolization (for treatment of knee OA) does not require additional bench, biocompatibility, sterilization, 
or pre-clinical animal testing beyond what was required for the reference device. All existing testing provided in the 
previous Embozene Microspheres premarket submissions remains applicable. 
 
Biocompatibility testing provided in the previous Embozene Microspheres premarket notification included: cytotoxicity, sensitization, irritation, sub-
acute and sub-chronic systemic toxicity, systemic toxicity- material mediated pyrogenicity, genotoxicity (bacterial mutagenicity, in-vitro 
chromosome aberration, in-vivo micronucleous assay), implantation, hemocompatibility (hemolysis, partial thromboplastin time, platelet/leukocyte 
counts). All tests passed, indicating that the device materials are biocompatible for its intended use. 
 
Performance testing provided in the previous Embozene Microspheres premarket notification included: microsphere size distribution, visual 
inspection, Ph of transport solution, osmolality of transport solution, microsphere suspension, catheter compatibility, and elution test. all tests 
passed demonstrating the device meets the predetermined performance requirements. 
 
Published literature on preclinical animal studies assessed the biocompatibility, safety, and efficacy of Embozene Microspheres in comparison with 
the Embosphere predicate and other embolization devices.  The devices were evaluated in a porcine kidney model to determine arterial 
distribution characteristics, inflammation and recanalization, impact on inflammatory tissue and foreign body reaction, and immunohistochemical 
inflammatory reactions. The results demonstrate a similar biological tissue response between the Embozene Microspheres and the Embosphere 
predicate device which supports substantial equivalence [18].  
 
A study by [CONTACT_772031], evaluated the inflammatory response and recanalization after embolization with the embolic agent based on a core and 
shell design with a hydrogel core of polymethylmethacrylate (PMMA) and a Polyzene-F nanoscale coating in a porcine kidney model [19]. It 
demonstrated good biocompatibility of the embolic material. As in other spherical embolic agents, recanalization can occur to some degree. 
 
Additionally, for labeling with MR compatibility, the proposed Embozene Microspheres were assessed and met requirements in the Guidance for 
Industry and Food and Drug Administration Staff Establishing Safety and Compatibility of Passive Implants in the MR Environment. 
 
2.2.[ADDRESS_1059949] been already investigated in several clinical studies. Stampfl U et al, investigated the safety and efficacy of uterine 
artery embolization using narrow-size-range polyphosphazene-coated hydrogel microspheres. Results demonstrated that uterine artery 
embolization with Embozene microspheres is a safe procedure. Its efficacy is demonstrated by [CONTACT_772032]-of-life scores during follow-up [20]. Sneets el al, demonstrated that 
Polyzene F–coated hydrogel microspheres for uterine artery embolization resulted in good dominant and overall tumor infarction in most patients, 
with corresponding improvement of symptoms [21]. 
 
Study number: s19-[ZIP_CODE]   Page 18 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February 2020Embolization of the geniculate artery was also investigated for the treatment of recurrent hemorrhage after hip and knee arthroplasty. Kalmar et al 
demonstrated 100% technical success rate, no procedure-related complications, and effectiveness in patients without underlying coagulopathy in 
preventing recurrences of spontaneous recurrent hematoma or hemarthrosis of the hip and the knee [22]. 
 
Recently, embolization of the geniculate artery was evaluated for the treatment of knee OA. Okuno et al, investigated the effects of embolizing 
abnormal blood vessels in people with mild to moderate knee OA [6]. Fourteen participants received transcatheter arterial embolization of 
function 
scores improved substantially at 1, 4, and [ADDRESS_1059950] procedure. No major adverse events occurred. One participant had a moderate 
subcutaneous hemorrhage at the puncture site that resolved within 1 week.  
 
In a follow-up study, Okuno et al, described the safety and efficacy of transcatheter arterial embolization in 72 patients with mild to moderate 
radiographic knee OA [23]. Clinical outcomes were evaluated at 1, 4, and 6 months and then every 6 months for a maximum of 4 years. Mean 
WOMAC pain scores significantly decreased from baseline to 1, 4, 6, 12, and 24 months after treatment (12.1 vs 6.2, 4.4, 3.7, 3.0, and 2.6; all P 
<.001). The WORMS score was evaluated at baseline and at 2 years after embolization in 35 knees and showed significant improvement of synovitis 
vs baseline (P < .0016) and no osteonecrosis or other evidence indicating aggressive progression of degenerative changes. There were no major 
adverse events related to the procedures. Specifically, there was no incidence of tissue necrosis, dermal ulcers, or peripheral paresthesia in any 
embolized territory during the follow-up period. Moderate subcutaneous hemorrhage at the puncture site in 12 patients resolved within 1 week. Four 
of seven patients treated with Embozene showed transient cutaneous color change on the treated knee, which resolved spontaneously within 1 
month.  
 
A recent study by [CONTACT_772033].al, showed improvement in the pain scores in 20 patients with knee osteoarthritis. The mean VAS improved from 76 mm 
 -month follow-up (P <.01). The m -month 
follow-up (P < .01). Self-limiting skin discoloration occurred in 65% patients and 10% of patients developed transient plantar sensory paresthesia. 
 
2.3 Rationale
The rational is based on a recent article by [CONTACT_772034] [23]. “The hallmark symptom of knee OA is pain. This is the symptom that drives individuals 
to seek medical attention and contributes to functional limitation and reduced quality of life [24, 25]. The alleviation of pain is the main motivation for 
treatment, including nonpharmacologic, pharmacologic, and surgical approaches. Severe and end-stage knee OA is successfully treated with joint 
replacement surgery, but effective management of mild to moderate radiographic knee OA refractory to conservative treatment can be difficult.” 
 
“Although OA was viewed as a “wear-and-tear” disease for many decades, it is now generally accepted to be a low-grade inflammatory disease of 
synovial joints and a biomechanical whole-organ disease [26]. Angiogenesis is believed to contribute to the genesis of inflammation and particularly 
to its maintenance [11]. The new increased vascular network provides inflammatory cells access to the synovium and other joint tissues and promotes 
additional hyperplasia and inflammation in other vessels, leading to bone and cartilage destruction [27]. In addition, studies on OA have shown that 
angiogenesis may contribute to chronic pain by [CONTACT_772035] [12, 15].” 
 
 
The current study seeks to determine whether transcatheter arterial embolization of abnormal neovasculature arising from the genicular arterial 
branches is safe and effective in the treatment of mild-to-moderate knee OA.   
 
Study number: s19-[ZIP_CODE]   Page 19 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February [ZIP_CODE].4 Potential Risks & Benefits 
2.4.1 Known Potential Risks
Potential adverse events related to the use of the device from the device from the device insert of directions for use (DFU) [attachment 1] and 
recent literature [6, 23]: 
 
- Possible adverse events:  
 Incomplete occlusion of vascular beds or territories may give rise to the possibility of post-procedural development of alternative vascular 
pathways, recanalization, or recurrence of symptoms 
 Post-embolization syndrome including fever, malaise, headache, and myalgia (body aches) 
 Transient, self-resolving cutaneous purpura / skin color change   
 Transient plantar or peripheral sensory paresthesia 
 Synovitis related symptoms including pain, stiffness or limited joint mobility  
 
- Rare adverse events:  
 Allergic reaction and foreign body reactions (e.g., pain, rash, fever, inflammation) 
 Capi[INVESTIGATOR_772013], passage/migration or placement of Embozene™ Microspheres, resulting in non-target embolization, ischemia, and / or 
ischemic infarction.   
 Non-target embolization to lower extremity vasculature resulting in vascular thrombosis and limp threatening ischemia  
 Vessel or lesion rupture  
 Tissue necrosis 
 Dermal ulcer 
 Tendon or ligament rupture  
 Osteonecrosis (rare- not reported in prior studies)  
 Joint infection (rare- not reported in prior studies)  
 
- Very rare adverse events:  
 Cerebrovascular accident (CVA)  
 Death  
 
Potential adverse events associated with angiography and catheterization of vessels include:  
 Nausea, vomiting, and/or allergic reaction anaphylaxis due to iodinated contrast used during embolization procedure (less possible)  
 Contrast-induced renal dysfunction (less possible)  
 Access site-related adverse events: bleeding, infection, hematoma formation, arteriovenous fistula, pseudoaneurysm (rare)  
Study number: s19-[ZIP_CODE]   Page 20 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February 2020 Vessels catherization associated adverse events: injury to catheterized vessels including vessel perforation, dissection, vasospasm, or 
thrombosis (rare)  
 Infection (rare)  
 
 
Potential adverse events associated with radiation exposure due to use of knee radiograph and fluoroscopy  
Deterministic radiation risks: Radiation-induced injuries to the skin and underlying tissues, which occur shortly after the exposure (rare) 
 Stochastic radiation risks: Radiation-induced malignancy which may occur later in life (rare)  
 
Potential adverse events associated with MRI knee:  
 Discomfort (possible) 
 Anxiety or claustrophobia (less possible)    
 Peripheral nerve stimulation casing tingling or twitching (rare)  
 Injury and burns related to metals (very rare, particularly with the MR screening performed prior to entering MR zone and subjects with 
contraindications to MR will be excluded from the study)  
 Pacemaker dysfunction (very rare; subjects with pacemakers will be excluded from the study) 
 Skin burns (very rare)   
 Tinnitus and hearing loss (very rare)  
 Quench (very rare)  
 
 
Potential adverse events associated with moderate sedation during procedure:  
 Over sedation (less possible)  
 Nausea, vomiting, and/or allergic reaction to medications / anaphylaxis (rare)  
 Respi[INVESTIGATOR_1399], myocardial infarction, and death (rare)   
 
Potential risks associated with study enrollment and ancillary study procedures:  
 Discomfort due to blood draws required for the study (possible) 
 Minor local discomfort due to the pressure of the ultrasound transducer on the skin during arterial access (possible)  
 Inconvenience at having to return for follow-up visits (possible)  
 Discomfort, Thrombophlebitis, bruising, bleeding, blood clot, presyncope or syncope (i.e. fainting) due to blood draws required for the 
study (less possible) 
 Psychological discomfort from clinical trial enrollment and completing study questionnaires (less possible)  
 Infection from blood draw for lab tests (rare)  
 Loss of confidentiality of medical records (rare) 
 
Risk minimization:  
The GAE procedure will be performed by [CONTACT_766616]-trained interventional radiologists who have expertise in endovascular techniques, particularly 
in selective catheterization and transcatheter embolization techniques.  
Study number: s19-[ZIP_CODE]   Page 21 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: [ADDRESS_1059951] projected for the procedure is thought to be around 30-75 gray/cm2.The effective radiation dose is approximately 0.003 
mSv from the x-ray of the knee if needed and a mean of 3.0 to 12 mSv from angiography of the lower extremity which is about 2-4 years of 
background radiation and significantly less than that of a cardiac catheterization (reference: Phys Med. 2009 Mar;25(1):25-30). Radiation exposure 
will be minimized to subjects under the principal of ‘as low as reasonably achievable’ (ALARA). For example, fluoroscopy will be performed with 
the lowest acceptable exposure for the shortest time necessary to perform the procedure (genicular artery embolization). Methods to reduce 
radiation-related adverse events include, but not limited to, tight collimation, use of pulsed fluoroscopy, and judicious image acquisition. 
 
Sterile instruments with a sterile technique will be used to minimize infection risk at the arterial access site. The arterial access site discomfort will 
be minimized by [CONTACT_772036]. Catheter access into the appropriate artery may be 
performed using ultrasound-guided arterial puncture to prevent inadvertent vessel puncture with subsequent bleeding. Real-time fluoroscopic 
monitoring of all catheter/wire manipulations will be used to prevent vascular injury.  
 
Cone beam CT, which provides cross sectional anatomic detail prior to embolization, will be available to the operating interventional radiologist. 
This angiographic technique can mitigate the risk of non-target embolization. The intent of this technique, as well as meticulous angiographic 
technique will be used to minimize the risk of non-targeted embolization, that could lead to skin or soft tissue/muscle injury.  
 
The subject will be monitored for the risk of an allergic response to iodinated contrast. To minimize the risk of renal dysfunction there will be use of 
non-ionic contrast agents, and appropriate pre-procedure hydration, when necessary. Subjects who report an allergic reaction to iodinated 
contrast will be pre-medicated as per routine allergy prophylaxis per standard of care. 
2.4.[ADDRESS_1059952]. Potential benefits to the subjects from participating in the study, based on prior clinical data 
available in the literature [6, 23] are:  
 Knee pain reduction  
 Physical function improvement  
 Synovitis reduction  
 
Other potential benefits under investigation:  
 Quality of life improvement  
 Delay in progression of disease (i.e. knee OA) 
[ADDRESS_1059953] 50% reduction in WOMAC 
Study number: s19-[ZIP_CODE]   Page 22 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: [ADDRESS_1059954]-intervention without an increase in baseline incidence of pain medication 
use or intra-articular injection.   
3.2 Secondary Objectives 
The secondary objectives of the study are to determine whether genicular artery embolization is effective in improving
1. Knee pain using an electronic VAS at 1-, 3-, and 12-months (and final 18-48 months visit) post intervention  
2. Knee pain using WOMAN pain score at 1- and 12-months (and final 18-48 months visit) post intervention 
3. knee stiffness using the WOMAC knee stiffness score at 1-, 3-, and 12- months (and final 18-48 months visit) post intervention  
4. Physical function using the WOMAC function score at 1-, 3-, and 12- months (and final 18-48 months visit) post intervention  
5. Self-reported quality of life using EQ-5D-5L scale at 1-, 3-, and 12- months (and final 18-48 months visit) post intervention [28]
6. Synovitis on MRI at [ADDRESS_1059955] intervention
 
Other secondary objectives are to assess  
1. Feasibility / technical success defined as successful selective catheterization of target vessel(s) and embolization from at least one feeding 
artery of the knee joint (with the embolization endpoint defined as suppression or reduction in the filling of (and therefore blood flow in) 
abnormal vessels visible on angiography.  
2. Reduction in frequency of pain medication usage over 30-day period assessed at baseline and at 1, 3, and [ADDRESS_1059956] 
intervention (acetaminophen, over the counter NSAIDs, prescription NSAIDs, opi[INVESTIGATOR_2438])  
3. Reduction in frequency of knee injection therapy over 12-month period (assessed at baseline and at 12-month follow-up visit post 
intervention)  
4. Reduction in frequency of need for physical therapy over 12-month period (assessed at baseline and at 12-month follow-up visit post 
intervention)
5. Safety evaluated by [CONTACT_772037] (AE), as well as type and severity of each adverse event.  
[ADDRESS_1059957] 50% reduction in WOMAC pain score at 3-month follow up 
visit. 40 patients will be required for this study. The study would accrue 50 patients to account for an attrition rate of 20%. 
 
Change in WOMAC pain score and pain VAS will be used as a measure of efficacy (i.e., pain reduction).  
 
WOMAC questionnaire is a widely used, disease-specific measure for knee OA. It includes 24 questions on daily activities. WOMAC pain score 
includes five questions regarding pain (pain during walking, stair climbing, nocturnal, rest, weight bearing); each question will be scored suing the 
Study number: s19-[ZIP_CODE]   Page 23 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February 2020following points: 0 for no pain, 1 for mild, 2 for moderate, 3 for severe, and 4 for extreme pain. possible score ranges for pain are 0–20. For this 
purpose, WOMAC Score will be calculated from the Knee injury and Osteoarthritis Outcome Score (KOOS) score which was developed as an 
extension of the WOMAC score with the purpose of evaluating short-term and long-term symptoms and function in subjects with knee injury and 
osteoarthritis. This means that the KOOS questionnaires will be administered to patients during visits and the WOMAC score will be calculated from 
the KOOS scores later at the time of data analysis. 
 
The electronic VAS is a horizontal line with no markings on the scale except “No pain” on the left (score: 0 mm) and “worst possible pain” on the 
right end of the scale (score: 100 mm). Subjects mark the VAS to indicate their current pain level, with 0 mm representing "No pain" and 100 mm 
representing "worst possible pain". In our study, subjects will be asked to mark their pain level on a paper VAS on study questionnaire form and will 
give a score between 0 to 100, which will be documented on the appropriate eCRF.  
 
 
All study variables will be collected on paper form [forms # 1-7 attached to this protocol] and study questionnaire forms (source documents) at the 
time of each clinic visit and transferred to eCRFs (TrialMaster; on NYU Langone secure servers) by [CONTACT_772038]. The 
source documents (paper forms) will be placed in secure locked folders with study documents (such as signed consent forms). The data dictionary 
of TrialMaster will be similar to the attached forms , [attachment 5].  
4.[ADDRESS_1059958] intervention. 
4.2.2 Secondary Study Endpoints Analysis  
Secondary efficacy endpoints are:
1- WOMAC pain score at 1- and 12- months (and final 18-48 months visit) post intervention
2- Pain electronic VAS at 1-, 3-, and 12- months (and final 18-48 months visit) post intervention  
3- Knee stiffness WOMAC score at 1-,3-, and 12- months (and final 18-48 months visit) post intervention  
4- Physical function WOMAC score at 1-, 3-, and 12- months (and final 18-48 months visit) post intervention  
5- Total WOMAC score at 1-,3-, and 12- months post intervention  
6- Self-reported quality of life using EQ-5D-5L scale at 1-, 3-, and 12- months (and final 18-48 months visit)  post intervention. 
7- MRI findings at 3- months post intervention 
8- Pain medication usage at 1-, 3-, and 12- months (and final 18-48 months visit) post intervention  
9- Injection therapy requirements (hyaluronic acid or steroid) at 12- months (and final 18-48 months visit) post intervention 
10- Physical therapy requirements at 12- months(and final 18-48 months visit)  post intervention 
11- Feasibility / technical success 
12- Laboratory findings at 1-, 3-, and 6- months (and final 18-48 months visit) post intervention  
Secondary safety endpoints are:  
13- Number/rate, severity, and description of complications, adverse events, or poor outcomes that are secondary to the procedure, which will 
be summarized using counts and simple statistics (i.e., mean number of patients with complications.)  
Study number: s19-[ZIP_CODE]   Page 24 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: [ADDRESS_1059959] meet all the following criteria:
1. 30-80 years of age of any gender and; 
2. Kellgren-Lawrence Grade 2, 3, or 4 (in select subjects who have no bony deformity)# knee OA on most recent knee radiograph obtained 
within 6 months of screening visit and;  
3. Knee pain resistant to conservative treatment for at least 3 months* (anti- inflammatory drugs, acetaminophen, physical therapy, muscle 
strengthening, or intra- articular injection of hyaluronic acid and/or steroids); and  
4.  meet 
inclusion criteria, the one with a higher VAS score will be chosen for the study (i.e., target knee). 
5. Willing, able, and mentally competent to provide informed consent and complete study questionnaires in English. The Study questionnaire 
is validated in English.  
 
# A recent study by [CONTACT_772029] S et al included subjects with KL grade 4 and published results showed, similar to other studies, clinical reduction in 
pain score with no added risks. The scientific rational for adding these subjects with KL grade 4 (severe knee OA with no bone deformity) is based 
on recent literature data (Citation: JB JS Open Access. [ADDRESS_1059960]-Dec; 6(4): e21.[ZIP_CODE].) 
 
*3 months was chosen because this time interval is thought adequate for knee pain to be considered refractory to conservativecare.
 
5.2 Exclusion Criteria 
An individual who meets any of the following criteria will be excluded from participation in this study: 
1. Active systemic or local knee infection or; 
2. Active malignancy or;  
3. Life expectancy less than 12 months or;  
4. Prior ipsilateral knee surgery (within 3 years of baseline visit), arthroscopic surgery (within 6 months of baseline), total or partial knee 
replacement regardless of timing  or;  
5. Ipsilateral knee intra-articular injection in the last 3 months or;  
6. Rheumatoid arthritis, spondyloarthropathies, crystal disease, gout, pseudogout, or lupus;  
7. Pregnant during the study period or;  
8. Renal dysfunction as defined by [CONTACT_89408] >1.6 dl/mg or eGFR <60 on blood tests obtained within 30 days of procedure or;  
9. Body weight greater than 200 Kg or;  
10. Uncorrectable coagulopathy (platelet count < 50,000, international normalized ratio >1.5 within 30 days of procedure; or 
11. Known history of contrast allergy resulting in anaphylaxis or; 
12. Known significant arterial atherosclerosis that would limit selective angiography and/or lower extremity symptoms thought to be secondary 
to arterial vascular disease (eg claudication, ischemic rest pain) 
13. Post-traumatic knee (if trauma occurred within 12 months of baseline or was associated with fractures) 
14. known avascular necrosis in the target knee  
15. Contraindications to MRI such as such as claustrophobia, metallic fragment/implants, pacemaker. 
Study number: s19-[ZIP_CODE]   Page 25 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February 2020 
5.3 Vulnerable Subjects
The study does not intend to recruit vulnerable subjects. The study will not recruit any children, pregnant women, fetuses, neonates, or prisoners.
5.4 Strategies for Recruitment and Retention
Participants will be recruited at the study investigator or sub-investigator clinical practices (visit 1). A study investigator or sub-investigator will 
assess the medical record of potential subjects for eligibility and provide eligible participants with written information (i.e. study brochure) regarding 
the study during the initial study visit [attachment 6] and obtain informed consent.  
 
IRB-approved study coordinator or co-investigator will guide interested people through written informed consent. knee X-rays will be graded with 
the Kellgren-Lawrence scale by a board certified, fellowship-trained musculoskeletal radiologist (Co-PI) [29]. Recruitment is expected to occur over 
3 years. To achieve primary objective, data from 40 patients will be required and the study would accrue 50 patients to account for an attrition rate 
of 20%. 
Only NYULH individuals who are listed on the NYU Langone Health IRB-approved protocol will approach patients for consent. A study brochure 
will be provided for potential subjects [attachment 6]. The study brochure will also be available in NYULH rheumatology, orthopedics, family 
medicine, and interventional radiology clinics and will be also disseminated on social media (e.g. Facebook, Twitter, blogging) to advertise for the 
study after IRB approval. The study brochure will include contact [CONTACT_772039]/or PI.  
 
Once enrolled, IRB-approved study coordinator will notify and remind participants about the visits.  
 
Participation in the study is voluntary; no financial incentives will be offered.  
 
5.4.1 Use of DataCore/Epic Information for Recruitment Purposes
This study will utilize EPIC to identify subjects. DataCore will request a report after obtaining IRB approval. The report will be requested to 
generate a list of potential subjects with a diagnosis of knee OA and who meet eligibility criteria from the electronic medical system of NYULH.  
 
The VIR / Radiology research coordinator, Bedros Taslakian (PI), Akhilesh Sista (co-PI), and Jonathan Samuels (co-PI) will have access to EPIC 
search results. The list will be filtered to identify patients who meet eligibility criteria listed in this protocol.  
 
The PHIs that will be extracted from the EPIC search will be patient’s name, MRN, contact [CONTACT_3031], and name [CONTACT_3669] [CONTACT_772040] (TP). The dataset will be deleted after discontinuation, termination, or completion of the study.  
 
Queries regarding eligible subjects will run during the course of the study once a month until discontinuation, termination, or completion of the 
study.  
 
Once potential subjects have been identified, the study team will notify the TP that they have patients eligible to participate as follow:  
 Treating physician will be notified that the study team will contact [CONTACT_93578], by [CONTACT_648], email, or the MyChart portal. 
Study number: s19-[ZIP_CODE]   Page 26 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: [ADDRESS_1059961] language [attachments 7&8] and study brochure [attachment 6].  
 
Patients will be contact[CONTACT_19904], the MyChart portal, MyChart recruitment tools through DataCore, and/or direct phone call using standard 
language attached to this protocol [attachments 7 and 8]. When sending recruitment information by [CONTACT_6968], SendSafe Secure email will be used to 
contact [CONTACT_1962]. 
 
Once contact [CONTACT_58661], the IRB-approved study brochure or language included in the approved study brochure (if contact [CONTACT_772041]) will be 
used to communicate the reason they are being contact[CONTACT_118674]. 
Should the potential subjects agree, the study team will provide the subjects with information regarding the next steps for participation.  
 
If a subject requests information regarding opting out of further recruitment for all research, subjects will be directed to contact [CONTACT_772042] [INVESTIGATOR_136] [EMAIL_14733] or at the office number [PHONE_16097]. The contact [CONTACT_772043]. If patient agrees to participate, he will be scheduled for a clinic visit with one of the investigators (visit 1) to further discuss the 
study, complete the screening elements, and obtain informed consent. 
 
If a subject requests information regarding opting out of further recruitment for all research, subjects will be directed to contact [CONTACT_772044] [EMAIL_6545] or [PHONE_7015]. 
5.[ADDRESS_1059962] will be enrolled in the study for approximately 13 months from the initial screening visit (visit 1; Day -30) until the last follow-up visit at 
[ADDRESS_1059963] intervention (visit 7; Day 360).  
5.6 Total Number of Participants and Sites 
Data from 40 participant will be required and the study would accrue 50 patients to account for an attrition rate of 20%.  
 
The study will be conducted only at NYULH Hospi[INVESTIGATOR_600]. No subjects will be enrolled at external national or international sites. 
 
5.[ADDRESS_1059964]. Participation of a patient in this clinical study may be 
discontinued for any of the following reasons: 
- The patient withdraws consent or requests discontinuation from the study for any reason; 
- Occurrence of any medical condition or circumstance that exposes the patient to substantial risk and/or does not allow the patient to 
adhere to the requirements of the protocol; 
- Any AE, clinically significant adverse event, severe laboratory abnormality, intercurrent illness, or other medical condition that indicates to 
the investigator that continued participation is not in the best interest of the patient; 
- Pregnancy during study period; 
Study number: s19-[ZIP_CODE]   Page 27 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February 2020- Patient failure to comply with protocol requirements or study-related procedures;  
- Termination of the study by [CONTACT_1034], the regulatory authority, FDA, or IRB.  
- The participant meets an exclusion criterion (either newly developed or not previously recognized) that precludes further study 
participation 
- Progression of osteoarthritis requiring surgical therapy 
- Patients found to have osteonecrosis on pre-procedural MRI  
5.7.[ADDRESS_1059965] be documented in the electronic case 
report form (eCRF). In the case of loss of follow-up, attempts to contact [CONTACT_772045]’s medical records.  
Every effort will be made to undertake protocol-specified safety follow-up procedures to capture AEs, serious adverse events (SAEs), and 
unanticipated problems (UPs). 
 
Withdrawn patients can be replaced. 
 
5.8 Premature Termination or Suspension of Study 
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause. Written notification, documenting the 
reason for study suspension or termination, will be provided by [CONTACT_87077], funding agency, the IDE 
sponsor and regulatory authorities. If the study is prematurely terminated or suspended, the PI [INVESTIGATOR_118627](s) for the termination or suspension. 
Circumstances that may warrant termination or suspension include, but are not limited to: 
 Determination of unexpected, significant, or unacceptable risk to participants 
 Insufficient compliance to protocol requirements 
 Data that are not sufficiently complete and/or evaluable 
 
Study may resume once concerns about safety, protocol compliance, data quality are addressed and satisfy the sponsor, IRB and/or FDA. 
6 Study Agent (Study device) and/or Procedural Intervention 
6.1 Study Device Description
Embozene™ Microspheres are spherical, tightly calibrated, biocompatible, nonresorbable, hydrogel microspheres coated with an inorganic 
perfluorinated polymer (Polyzene™-F). The microspheres intended to occlude vasculature for the purpose of blocking blood flow to a target tissue. 
They are available in prefilled syringes in a range of sizes suitable for embolic therapy. The microspheres are compressible to enable smooth 
delivery through the indicated delivery catheter and color-coded by [CONTACT_772046].  
 
Embozene Microspheres are intended for embolization of arteriovenous malformations and 
hypervascular tumors, including uterine fibroids and hepatoma, and for embolization of prostatic 
Study number: s19-[ZIP_CODE]   Page 28 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February 2020arteries for symptomatic benign prostatic hyperplasia. This device is not intended for neurovascular use. The device is FDA approved for above 
indications (FDA approved for treatment of BPH; FDA approval 510(K) # K180102; 510(k) premarket notification of intent to market the device 
FDA 510(k) # K141209) 
 
There are no known chemical interactions between Embozene Microspheres and pharmaceuticals. 
 
IDE for the purpose of this study was obtained.  
6.1.1 Acquisition
Embozene™ Microspheres will be supplied by [CONTACT_3455].  
6.1.[ADDRESS_1059966] Storage and Stability 
As per manufacturer’s instructions specified in the DFU, the device should be stored in a cool, dry, dark place. Product must be used prior to 
expi[INVESTIGATOR_772014]. The investigational device will be stored in a secure locked cabinet in the interventional radiology storage area (Tisch 
hospi[INVESTIGATOR_307], 2nd floor) and only the PI [INVESTIGATOR_772015]. 
6.1.[ADDRESS_1059967] suspended in a non-pyrogenic, sterile transport solution of 
physiological saline. The total volume of Embozene Microspheres including transport solution is approximately 7 ml. 
 
Prior to embolization, the transport solution will be eliminated from the syringe. An embolic mixture will be prepared by [CONTACT_1583] 9 cc saline + [ADDRESS_1059968] (Embozene Microspheres) for a total of 20 cc embolic mixture.   
6.1.5 Dosing and Administration
The embolic mixture will be injected in small increments until blood flow stagnates in the target artery (1 cc embolic mixture injected over 2 
minutes, followed by 1 cc saline delivered slowly, then 3 cc saline flush).  
6.1.6 Route of Administration
The embolic mixture will be injected in small increments in the target geniculate artery(ies) after selective catheterization of the target vessel(s) 
using a microcatheter to reach distal arteries while avoiding branches that do not feed abnormal vessels. 
6.1.7 Duration of Therapy
Treatment will be completed during one interventional session (visit 3, day 0)
Study number: s19-[ZIP_CODE]   Page 29 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February [ZIP_CODE].1.8 Device Specific Considerations
e syringes will be 
used for this study and are supplied in prefilled yellow syringes.  
6.2 Study Procedural Intervention(s) Description 
On the day of the procedure (visit 3, day 0), the subjects will be given the choice of receiving intravenous anxiolytic and analgesic medication 
(moderate sedation) during procedure or proceeding with local anesthetic only. Arterial access site will be prepped and draped using sterile 
technique. Femoral artery access will be obtained with a micropuncture needle set and a vascular sheath or a guiding catheter will be placed in 
the femoral artery to maintain vascular access. Ultrasound-guided access may be used. A guiding catheter will be introduced and lower extremity 
digital subtraction angiography will be performed to depi[INVESTIGATOR_772016], superior and inferior lateral genicular arteries, superior 
and inferior medial genicular arteries, and the median genicular artery in all patients. Angiography will be performed to identify abnormal knee 
neovasculature arising from one or more of geniculate arterial branches.  
 
After localizing the abnormal neovessels (abnormal vessels appear as tumor blush–type enhancement in the arterial phase, often accompanied by 
[CONTACT_772047] /hypervascular synovial tissue in the region of the target knee joint), a microcatheter will be inserted coaxially through the 
guiding catheter and selectively placed in the targeted artery(ies). If there is uncertainty about the angiographic findings, pre-embolization 
simulation can be performed with contrasted cone beam CT on the procedure table. This will allow the operators to know exactly what tissues will 
be receiving the microspheres. The abnormal vessels will be embolized with 250 m Embozene™ Microspheres solution under direct fluoroscopic 
visualization to prevent reflux and non-target embolization. Multiple geniculate arteries may be embolized until neovascularity is no longer seen.  
The embolic mixture will be prepared by [CONTACT_1583] 9 cc of saline + [ADDRESS_1059969] ‘pruning” of the hypervascular synovium ’ (slowed 
antegrade flow of contrast).in the target artery(ies) (1 cc embolic mixture injected over 2 minutes, followed by 1 cc saline delivered slowly, then 3 
cc saline flush). In some cases, more selective catheterization will be performed by [CONTACT_772048]. After embolization, a repeat lower extremity angiogram and contrasted cone beam CT (if needed) will 
then be performed to evaluate for success of embolization and to exclude complication. The catheter(s) and sheath will be removed, and 
hemostasis of the arterial access will be achieved by [CONTACT_13247]-approved arterial closure device or manual compression and bed rest for 2-[ADDRESS_1059970] procedure.  
 
Disposable syringes which spherical particulate will be discarded as medical waste and packaging will be kept in a secure location until the study 
is completed. Packages will be disposed of upon completion of the study. 
6.2.1 Administration of Procedural Intervention
Procedure will be performed by [CONTACT_772049]. The 
interventional procedure will be performed during one session (day 0) with an approximate duration of the procedure estimated between 1-3 
hours. Additional 2-6 hours will be needed after hemostasis of the access femoral artery is achieved for monitoring / observation. In general, the 
subject will be discharged home the same day (<23 hours) unless a complication arises that requires inpatient admission for management of the 
complication. 
Study number: s19-[ZIP_CODE]   Page 30 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February [ZIP_CODE] Study Procedures and Schedule 
7.1 Study Procedures/Evaluations
7.1.1 Study Specific Procedures 
 Medical history  
o Complete medical history will be obtained from medical records if available and/or by [CONTACT_772050].  
 History of previous and concomitant treatment 
o Knee injections and frequency over the [ADDRESS_1059971] intervention study visits. Medication history will focus 
on medications currently taken for the treatment of knee OA; including prescription and over-the-counter medications for pain.  
o Physical therapy and frequency over the 12 months  
o Weight loss / gain  
 Focused physical examination:  
o Vital signs (temperature, blood pressure, heart rate, oxygen saturation, height, weight, BMI)  
o Focused knee examination.  
o Lower extremity pulses  
 Imaging assessment with knee MRI 
o Baseline and follow-up (at 3 months) knee MRI will be performed.  
o Knee MRI protocol will include: Axial t2 FS, Sagital PD, Sagital T2 FS, Coronal PD, Coronal PD FS, non-contrast axial and sagittal 
T1 FS.  
o Imaging variables collected for this study is found in the attached eCRFs 
 A discussion of the results of any study specific procedures (e.g., radiographic or other imaging or laboratory evaluations) will be provided 
to participant after the completion of the study unless these information represent a significant health-related issue. 
 Laboratory tests:  
o Baseline and follow-up (at 1-, 3-, and 12-, 18-48 months) laboratory tests will be obtained  
 Administration of questionnaires or other instruments for patient-reported outcomes: 
o Electronic VAS  
o KOOS questionnaire  
o Self-reported quality of life EQ-5D-5L questionnaire  
 
7.1.[ADDRESS_1059972] of care imaging assessment with knee radiograph: 
o Knee radiograph obtained within 6 months of the screening will be used to assess the Kellgren-Lawrence (KL score) 
o A new knee radiograph will be obtained during or prior to visit 2 if no recent (within 6-month) radiograph of the target knee is 
available  
o Knee radiograph protocol: AP weightbearing, lateral, sunrise views  
o KL score will be assessed by a blinded musculoskeletal radiologist (one of co-investigators)  
Study number: s19-[ZIP_CODE]   Page 31 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February 2020 
7.2 Laboratory Procedures/Evaluations
7.2.1 Laboratory Evaluations 
Baseline laboratory tests on peripheral venous blood drown from patient during clinic visit #2 (if not available within the last 30 days prior to 
procedure.  
 
 Hematology:  Complete blood count (CBC)  
 Biochemistry:  Basic metabolic panel (BMP)  
 Coagulation profile: INR 
 Pregnancy test : point pregnancy test will be performed prior to procedure as standard procedure prior to fluoroscopic examination.  
 
Baseline and follow-up laboratory tests on urine samples and peripheral venous blood drown from patient during clinic visits (2, 5, 6, 7). 
Approximately 10 cc of blood will be collected from peripheral venous blood in each visit that requires collection of blood samples.  
 Inflammatory biomarkers: 
o IL-6, 
o MMP (total activity assay), 
o IL1Ra,  
o sRAGE,  
o hsCRP,  
o VEGF,  
o S100 protein  
 Pain biomarkers  
o Substance P 
o NGFb,  
o CCL2  
 Matrix degradation collagen biomarkers  
o CTX-II and CTX-I. 
Type IV collagen markers (C4M, PRO-C4)*
PRO-C6 measuring endothelium dysfunction*
Synovial and cartilage markers (C2M, ARGS, CRPM, C1M, C3M)*
The current approved IRB protocol involves collection of blood and urine from all subjects at baseline, 1-month, 3-month, and 12-month follow 
up to analyze multiple serum, urine, and plasma biomarkers. We are requesting IRB modification to add an optional final visit for patients who 
completed [ADDRESS_1059973] 31, 2024 after obtaining informed consent. This visit will include blood and urine collection similar to 
prior visits. No significantincrease in risk. At the patient’s request, t his visit can be performed by a telemedicine visit, a phone call, or via a secure 
email to participant. In this case, the informed consent can be obtained via phone and the coordinator / investigator will sign in the presence of a 
witness. If the visit is performed via telemedicine or phone call, the research coordinator will ask the patient the questions and document the answers. 
If performed via email, the coordinator will send the questionnaire to patient using a secure email (sendsafe) and participants can email it back to 
Study number: s19-[ZIP_CODE]   Page 32 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February 2020research coordinator or PI. This addition of a virtual visit will not increase the risk of participants; in contrary, it will provide the patient with the benefit 
of having a longer follow up with study team. If the visit is performed remotely, blood and urine samples, used for biomarkers and exploratory analysis 
points, will not be required.  
 
* A portion of the collected material as part of the approved protocol, including blood, and urine, may be sent for additional biomarker analysis 
to outside laboratory /subcontractors. These additional biomarkers are marked with an Asterix above are: type IV collagen markers (C4M, PRO-
C4);  PRO-C6 measuring endothelium dysfunction; synovial and cartilage markers (C2M, ARGS, CRPM, C1M, C3M). All samples sent to outside 
collaborations / laboratories will be deidentified by [CONTACT_772051]’ identity. No additional 
samples will be collected as part of the modification. No additional risks to subjects are expected. 
- Optional segment: The evaluation of the ADDITIONAL biomarkers in the outside lab will be optional for subjects. The biomarkeranalysis 
performed by [CONTACT_35836]-approved study team members at NYU will remain unchanged as part of the modification. 
- Storage location: These samples (serum, plasma, and urine samples collected as part of the approved research protocol are stored and 
identified by [CONTACT_772052][INVESTIGATOR_307]. When samples are sent to an outside 
laboratory (optional part of the study), the remaining samples will be discarded after the biomarker analysis is performed and results 
obtained.  
- Access to samples: IRB-approved study team members from NYU Langone Orthopedic Hospi[INVESTIGATOR_772017].  
- Protecting subject anonymity: Study team members who have access to the samples will received the blood / urine tubes labeledwith 
study subject number and date of collection. 
- Samples will be stored until the end of data analysis and study closure. All samples sent to outside collaborations / laboratories will be 
de-identified by [CONTACT_772053]
7.3 Study Schedule
7.3.1 Screening 
Screening Visit (Visit 1, Day -30 to -2)- In rheumatology or vascular and interventional radiology clinic   
 Obtain informed consent of potential subject (If the subject wishes to take more time to review the study before enrolling, he/she may 
complete the consent process at the beginning of the next visit) 
 Provide a copy of informed consent and study brochure to subject  
 Review subject’s eligibility based on inclusion/exclusion criteria 
 Collect demographic variables  
 Obtain medical history  
 Schedule study visits for eligible participants  
Study number: s19-[ZIP_CODE]   Page 33 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February 2020Note: if subject prefers, visits [ADDRESS_1059974] and the original filed in the study files. 
7.3.2 Enrollment/Baseline (Visit 2, Day -29 to -1)- In interventional radiology clinic  
 Verify informed consent of potential participant (study consent)   
 Verify subject’s eligibility  
 Targeted physical exam  
 Administration of study questionnaires 
 Previous / concomitant treatments 
 Baseline MRI (if one is not available within the last 3 months)  
 Baseline knee radiograph (if one is not available within the last 6 months)  
 Peripheral venous blood draws and urine sample (baseline laboratory tests)   
 Note: Subjects will be required to withhold pain medications 24 hours prior to screening and each visit for the evaluation of pain 
7.3.3 Interventional visit (visit 3, Day 0) 
Within [ADDRESS_1059975] any immediate complications / adverse events detected during the procedure or observation period (if applicable)  
 Subjects will be given a phone number to reach a physician 24 hours a day to report any adverse symptoms and receive medical advice 
7.3.4 Follow-up Visits
[IP_ADDRESS] Follow up visit at 1 day (Visit #4; day 1 /+3 days)
 Subjects will be seen in clinic or contact[CONTACT_772054]’s preference the day following GAE (+3 days). As most 
complications of the procedure will be evident within this time period, this visit is to evaluate for early AE’s. If AE is suspected based 
on change in pain scores or functionality, further assessment and management will be performed based on the nature of suspected 
adverse event.  
[IP_ADDRESS] Follow up visit at 1-month (Visit 5, Day 30 +/- 10) 
 Obtain medical history  
 Record adverse events as reported by [CONTACT_145855] (if applicable)  
 Targeted physical exam 
 Administration of study questionnaires 
 Previous / concomitant treatments, including medical history  
 Peripheral venous blood draw and urine sample to perform follow-up laboratory tests  
Study number: s19-[ZIP_CODE]   Page 34 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February 2020 Note: Subjects will be required to withhold pain medications 24 hours prior to screening and each visit for the evaluation of pain 
[IP_ADDRESS] Follow up visit at 3 months (Visit 6, Day 90 +/- 10)   
 Obtain medical history  
 Record adverse events as reported by [CONTACT_145855] (if applicable)  
 Targeted physical exam 
 Administration of study questionnaires 
 Previous / concomitant treatments, including medical history  
 Peripheral venous blood draw and urine sample to perform follow-up laboratory tests  
 Follow-up knee MRI 
 Note: Subjects will be required to withhold pain medications 24 hours prior to screening and each visit for the evaluation of pain 
[IP_ADDRESS] Follow up visit at 12 months (Visit 7, Day 360 +/- 10)   
 Obtain medical history  
 Record adverse events as reported by [CONTACT_145855] (if applicable)  
 Targeted physical exam 
 Administration of study questionnaires 
 Previous / concomitant treatments, including medical history  
 Peripheral venous blood draw and urine sample to perform follow-up laboratory tests  
 Note: Subjects will be required to withhold pain medications 24 hours prior to screening and each visit for the evaluation of pain 
7.3.5 Follow up visit at 18-48 month (visit 8):  
This visit is optional to all study participants who completed [ADDRESS_1059976] adverse events as reported by [CONTACT_145855] (if applicable)  
 Targeted physical exam 
 Administration of study questionnaires 
 Previous / concomitant treatments, including medical history  
 Peripheral venous blood draw and urine sample to perform follow-up laboratory tests  
 Note: Subjects will be required to withhold pain medications 24 hours prior to screening and each visit for the evaluation of pain 
 
7.3.6 Withdrawal/Early Termination Visit
Obtain medical history 
 Record adverse events as reported by [CONTACT_145855] (if applicable)  
 Targeted physical exam 
Study number: s19-[ZIP_CODE]   Page 35 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February 2020 Administration of study questionnaires 
 Previous / concomitant treatments, including medical history  
 Peripheral venous blood draw and urine sample to perform follow-up laboratory tests  
 Note: Subjects will be required to withhold pain medications [ADDRESS_1059977] including the reason for the visit and assessment / 
management plan as determined by [CONTACT_99816].  
 
7.4 Concomitant Medications, Treatments, and Procedures 
 
All relevant concomitant medications taken during study participation, as well as treatments and procedures will be recorded on eCRFs. 
Medications to be reported in the eCRF are concomitant prescription medications, over-the-counter medications and non-prescription medications 
used pain management. For this protocol, a prescription medication is defined as a medication that can be prescribed only by a properly 
authorized/licensed clinician. 
Note: Subjects will be required to withhold pain medications 24 hours prior to screening and each visit for the evaluation of pain 
 
  
7.5 Rescue Medications, Treatments, and Procedures
In the event of non-target embolization during the procedural visit leading to limb ischemia, subsequent interventions and / or medical 
management may be required for treatment of limb ischemia.  
 
7.[ADDRESS_1059978] of care treatment for knee OA.
 
8 Assessment of Safety
8.1 Specification of Safety Parameters 
Safety parameters include the number, severity, causality, timing, and description of complications, adverse events, or poor outcomes that are 
secondary to the procedure.  
 
Study number: s19-[ZIP_CODE]   Page 36 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February [ZIP_CODE].1.1 Definition of Adverse Events (AE)
An adverse event  (AE) is any symptom, sign, illness or experience that develops or worsens in severity during the course of the study. 
Intercurrent illnesses or injuries should be regarded as adverse events.  Abnormal results of diagnostic procedures on target knee in the follow-up 
period after the study intervention are considered to be adverse events if the abnormality: 
 results in study withdrawal 
 is associated with a serious adverse event 
 is associated with clinical signs or symptoms 
 leads to additional treatment or to further diagnostic tests 
 is considered by [CONTACT_1372] 
8.1.2 Definition of Serious Adverse Events (SAE) 
Serious adverse events are considered to be those resulting in an unplanned increase in the level of care, prolonged hospi[INVESTIGATOR_059], permanent 
adverse sequelae, or death. 
 
A serious adverse event  is any AE that is:  
 fatal 
 life- or limb- threatening 
 requires or prolongs hospi[INVESTIGATOR_226718] 
 a congenital anomaly or birth defect 
 an important medical event 
 
Important medical events are those that may not be immediately life or limb threatening but are clearly of major clinical significance. They may 
jeopardize the subject and may require intervention to prevent one of the other serious outcomes noted above.  
 
All adverse events that do not meet any of the criteria for serious should be regarded as non-serious adverse events .  
 
8.1.3 Definition of Unanticipated Problems (UP)
Unanticipated Problems Involving Risk to Subjects or Others
Any incident, experience, or outcome that meets all of the following criteria:  
Unexpected in nature, severity, or frequency (i.e. not described in study-related documents such as the IRB-approved protocol or consent 
form, the investigators brochure, etc)
 Related or possibly related to participation in the research (i.e. possibly related means there is a reasonable possibility that the incident 
experience, or outcome may have been caused by [CONTACT_3459])
 Suggests that the research places subjects or others at greater risk of harm (including physical, psychological, economic, or social harm). 
Study number: s19-[ZIP_CODE]   Page 37 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: [ADDRESS_1059979], problem, or death was not previously identified in nature, severity, or degree of incidence in the 
investigational plan or application, or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare 
of subjects (21 CFR 812.3(s)). 
 
8.2 Classification of an Adverse Event 
8.2.1 Severity of Event 
The Investigator will assess the severity (intensity) of each adverse event as mild, moderate,
severe, life-threatening / disabling event, or death/ unexpected pregnancy abortion.  The investigator will also categorize each adverse event as to 
its potential relationship to study drug using the categories of yes or no. 
 
The severity and causality of all adverse events will be graded according to the new adverse event classification by [CONTACT_772055] [30], as follows:  
 
- Mild AE:  No therapy or nominal (non-substantial) therapy (postprocedural imaging performed and fails to show manifestation of AE); near 
miss (eg, wrong site of patient prepared, recognized and corrected before procedure, wrong patient information entered for procedure);  
- Moderate AE:  moderate escalation of care, requiring substantial treatment, eg, intervention (description of intervention and result of 
intervention) under conscious sedation, blood product administration, extremely prolonged outpatient observation, or overnight admission 
after outpatient procedure not typi[INVESTIGATOR_140281] (excludes admission or hospi[INVESTIGATOR_772018]);  
- Severe AE:  marked escalation of care, ie, hospi[INVESTIGATOR_772019] > 24 hours, hospi[INVESTIGATOR_772020], inpatient transfer from regular floor/telemetry to intensive care unit, or complex intervention 
performed requiring general anesthesia in previously non-intubated patient (generally excludes pediatrics or in circumstances in which 
general anesthesia would primarily be used in lieu of conscious sedation, eg, in mentally challenged or severely uncooperative patients);  
- Life-threatening or disabling event:  eg, cardiopulmonary arrest, shock, organ failure, unanticipated dialysis, paralysis, loss of limb or 
organ;  
- Patient death or unexpected pregnancy abortion .  
 
For AEs not included in the protocol defined grading system, the following guidelines will be used to describe severity. 
 
 Mild – Events require minimal or no treatment and do not interfere with the participant’s daily activities. 
 Moderate  – Events result in a low level of inconvenience or concern with the therapeutic measures. Moderate events may cause some 
interference with functioning. 
 Severe – Events interrupt a participant’s usual daily activity and may require systemic drug therapy or other treatment. Severe events are 
usually potentially life-threatening or incapacitating. 
 
8.2.2 Relationship to Study Device  
Study number: s19-[ZIP_CODE]   Page 38 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February 2020For all collected AEs, the clinician who examines and evaluates the participant will determine the AE’s causality based on temporal relationship 
and his/her clinical judgment. The degree of certainty about causality will be graded using the categories below according to the new adverse 
event classification by [CONTACT_772056] 1: AE not caused by [CONTACT_42540]. The AE is completely independent of study drug administration, and/or evidence exists that the 
event is definitely related to another etiology. There must be an alternative, definitive etiology documented by [CONTACT_15370].
 Category 2: Unknown whether AE was caused by [CONTACT_164532]. 
Category 3: AE caused by [CONTACT_164532]. There is clear evidence to suggest a causal relationship, and other possible contributing factors
can be ruled out.
 
The definition implies a reasonable possibility of a causal relationship between the event and the 
study device. This means that there are facts (evidence) or arguments to suggest a causal relationship . 
 
The following factors should also be considered: 
- The temporal sequence from study procedure: The event should occur after the study procedure. The length of time from study procedure 
to event should be evaluated in the clinical context of the event. 
- Underlying, concomitant, intercurrent diseases: Each report should be evaluated in the context of the natural history and course of the 
disease being treated and any other disease the patient may have. 
- Concomitant procedures / treatments: The other drugs the patient is taking or the treatment the patient receives should be examined to 
determine whether any of them might be recognized to cause the event in question. 
- Known response pattern for this class of study procedure: Clinical and/or nonclinical data may indicate whether a particular response is 
likely to be a class effect. 
- Exposure to physical and/or mental stresses: The exposure to stress might induce adverse changes in the recipi[INVESTIGATOR_23567] a logical 
and better explanation for the event. 
8.2.3 Expectedness
The PI [INVESTIGATOR_118631]. An AE will be considered unexpected if the nature, severity, 
or frequency of the event is not consistent with the risk information previously described for the study device. 
 
8.3 Time Period and Frequency for Event Assessment and Follow-Up
The occurrence of an AE or SAE may come to the attention of study personnel during study visits and interviews of a study participant presenting 
for medical care, or upon review by [CONTACT_772057]. All AEs including local and systemic reactions not meeting the criteria for SAEs will be 
captured on the appropriate eCRF. Information to be collected includes event description, time of onset, clinician’s assessment of severity, 
relationship to study procedure (assessed only by [CONTACT_8703] a diagnosis), and time of resolution/stabilization of 
the event. All AEs occurring while on study must be documented appropriately regardless of relationship. All AEs will be followed to adequate 
resolution. 
 
Any medical condition that is present at the time that the participant is screened will be considered as baseline and not reported as an AE. 
However, if the study participant’s condition deteriorates at any time during the study, it will be recorded as an AE. UPs will be recorded in the data 
collection system throughout the study. 
Study number: s19-[ZIP_CODE]   Page 39 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: [ADDRESS_1059980] all reportable events with start dates occurring any time after informed consent is obtained until 7 (for non-serious AEs) or 30 
days (for SAEs) after the last day of study participation. At each study visit, the investigator will inquire about the occurrence of AE/SAEs since the 
last visit. Events will be followed for outcome information until resolution or stabilization.  
 
All unresolved adverse events should be followed by [CONTACT_1374], the subject is lost to follow-up, or the adverse 
event is otherwise explained.  At the last scheduled visit, the investigator should instruct each subject to report any subsequent event(s) that the 
subject, or the subject’s personal physician, believes might reasonably be related to participation in this study.  The investigator should notify the 
study sponsor of any death or adverse event occurring at any time after a subject has discontinued or terminated study participation that may 
reasonably be related to this study.  The sponsor should also be notified if the investigator should become aware of the development of cancer or 
of a congenital anomaly in a subsequently conceived offspring of a subject that has participated in this study.  
8.4 Reporting Procedures – Notifying the IRB  
8.4.1 Adverse Event Reporting 
The principal investigator [INVESTIGATOR_772021] a study within five working days  of learning about the event using Research Navigator. 
8.4.2 Serious Adverse Event Reporting
Serious adverse events will be captured from the time of the main study’s informed consent through [ADDRESS_1059981] under 812.46(b) shall report the results of such evaluation to 
FDA and to all reviewing IRB's and participating investigators within [ADDRESS_1059982] as FDA requests 
 
8.4.3 Unanticipated Problem Reporting
Incidents or events that meet the OHRP criteria for UPs require the creation and completion of an UP report form. It is the site investigator’s 
responsibility to report UPs to their IRB and to the DCC/study sponsor. The UP report will include the following information: 
 
 Protocol identifying information: protocol title and number, PI’s name, and the IRB project number; 
 A detailed description of the event, incident, experience, or outcome; 
Study number: s19-[ZIP_CODE]   Page 40 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February 2020 An explanation of the basis for determining that the event, incident, experience, or outcome represents an UP; 
 A description of any changes to the protocol or other corrective actions that have been taken or are proposed in response to the UP. 
 
To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline: 
 
 UPs that are SAEs will be reported to the IRB and to the DCC/study sponsor within 5 working days  of the investigator becoming aware of 
the event. 
 Any other UP will be reported to the IRB and to the DCC/study sponsor within [ADDRESS_1059983] participating in the study is found to be pregnant during the study period, participant will immediately be withdrawn from the study 
and IRB will be informed.  
8.5 Reporting Procedures – Notifying the Study Sponsor
The study clinician will complete a SAE Form within the following timelines:
 
 All deaths and immediately life-threatening events, whether related or unrelated, will be recorded on the SAE Form and submitted to the 
study sponsor (PI) within 24 hours of awareness.  
 Other SAEs regardless of relationship will be submitted to the study sponsor (PI) within [ADDRESS_1059984] the understanding of the event.  Significant new information on 
ongoing unanticipated adverse effects shall be provided promptly to the study sponsor. 
 
8.6 Reporting Procedures – Notifying the FDA 
The study sponsor is required to report certain study events in an expedited fashion to the FDA.  These written notifications of adverse events are 
referred to as IDE safety reports.  
 
 Within 10 working days (via telephone or facsimile report)  
Any study event that is: 
– associated with the use of the study device, and
– unanticipated,  
regardless of the seriousness of the event. 
Study number: s19-[ZIP_CODE]   Page 41 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February 2020 
 Within 5 working days (via written report)  
– Protocol deviation to protect the life of the subject in emergency 
– Withdrawal of IRB approval 
– Lack of informed consent 
 
Additional reporting requirements 
Sponsors are also required to identify in IDE safety reports all previous reports concerning similar adverse events and to analyze the significance 
of the current event in light of the previous reports. 
 
Reporting Process 
Adverse events may be submitted on FDA Form 3500A (MEDWATCH Form) [attachment 9], or in a narrative format.  
 
8.7 Safety Oversight
It is the responsibility of the Principal Investigator [INVESTIGATOR_133605].  This safety monitoring will include careful assessment and 
appropriate reporting of adverse events as noted above, as well as the construction and implementation of a site data and safety-monitoring plan. 
Medical monitoring will include a regular assessment of the number and type of serious adverse events. Data (demographics, eligibility criteria), 
screening methods, and adverse events will be assessed by [CONTACT_978] [INVESTIGATOR_63124] a fellowship trained interventional radiologist and licensed physician 
monthly to ensure study safety, compliance, and integrity/accuracy of data in accordance with the data safety monitoring plan.  
Administration of study procedure will be halted when three moderate or higher grade AEs determined to be “related” are reported to the sponsor 
(PI). The PI [INVESTIGATOR_772022] 3 event is reported and enrollment screens will stop accepting new 
study participants. The study sponsor will convene a meeting with study investigators by [CONTACT_772058]. The study sponsor will inform the IRB and FDA of the temporary halt and the disposition 
of the study. 
 
The outcomes of these reviews, when adverse events are captured will be communicated directly with the IRB. A summary of these reviews will 
be submitted to the IRB as part of an annual progress report at Continuing Review. 
 
Specific data safety monitoring plan is listed below:  
1- Vascular injury / non-target embolization to lower extremity, bleeding, access site complications will be monitored as follows:  
a. On the day of procedure, interventional radiologist (investigator) performing the procedure will assess access site and lower 
extremity pulses and document  
b. Day 1 visit / telemedicine visit: investigator will assess for symptoms in the target lower extremity (pain, swelling at access site and 
document findings  
c. 4 weeks follow up visit: investigator will assess groin access site for hematoma, pseudoaneurysm and assess lower extremity 
pulses 
 Skin ulceration, cutaneous purpura, plantar or peripheral sensory paresthesia will be monitored as follows:  
o Each follow up visit, an investigator will assess for symptoms and signs in the target lower extremity and document  
Study number: s19-[ZIP_CODE]   Page 42 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February 2020  
9 Clinical Monitoring/Quality Assurance
Clinical site monitoring is conducted to ensure that the rights and well-being of human subjects are protected, that the reported trial data are 
accurate, complete, and verifiable, and that the conduct of the trial is in compliance with the currently approved protocol/amendment(s), with GCP, 
and with applicable regulatory requirement(s). 
 
 Monitoring for this study will be performed by [CONTACT_9154] [CONTACT_39773] 3 months. 
 Monitoring activities include communication with the sub-investigators and study site staff; review of the study site’s processes, procedures, 
and records; and verification of the accuracy of data. 
 
10 Statistical Considerations 
10.1 Statistical and Analytical Plans (SAP) 
A formal SAP will not be performed prior to database lock since this study is a pi[INVESTIGATOR_772023]. 
10.2 Statistical Hypotheses 
This is a single arm study (i.e., no sham, placebo or alternative treatment included). The primary objective (clinical success rate) is a binary 
assessment of whether or not each patient shows at least a 50% reduction in WOMAC pain scores from baseline (pre-treatment) to post-treatment 
follow-up at [ADDRESS_1059985] the null hypothesis (H0) that the true proportion (PT) of patients that will manifest a positive treatment response, is no 
greater than 0.[ADDRESS_1059986] 95% 
confidence interval (CI) per the Blyth-Still-Casella method (31). The treatment will be declared a success if the data support the conclusion that at 
least 75% of treated patients can be expected to show a positive response. The treatment will be considered unworthy of additional study without 
further development if the data are consistent with the conclusion that no more than 50% of treated patients can be expected to show a positive 
response.  
10.3 Analysis Datasets
Participants who complete all follow-up visits will be included in the study. 
 
Study number: s19-[ZIP_CODE]   Page 43 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: [ADDRESS_1059987] 95% 
confidence interval (CI) per the Blyth-Still-Casella method (31).  
10.4.1 General Approach
This is a single arm study (i.e., no sham, placebo or alternative treatment included). The primary objective (clinical success rate) will be assessed 
as a binary outcome of whether or not each patient shows at least a 50% reduction in WOMAC pain scores from baseline (pre-treatment) to post-
treatment follow-up at [ADDRESS_1059988] 95% confidence interval (CI) 
per the Blyth-Still-Casella method. WOMAC pain score, pain VAS, WOMAC stiffness and physical activity scores will be assessed as mean and 
standard deviation.   
10.4.2 Analysis of the Primary Endpoint(s) 
The primary endpoint is the clinical success rate defined as at least 50% reduction in WOMAC pain score at 3-month follow-up compared to 
baseline as a binary assessment.  
10.4.3 Analysis of the Secondary Endpoint(s)
Analysis of secondary endpoints include: (1) changes in the mean WOMAC and VAS pain scores, the mean WOMAC knee stiffness and physical 
function scores and the total WOMAC knee physical function score; (2) the technical success rate (defined as the proportion of patients for whom 
the procedure was successfully completed); (3) the adverse event rate (defined as the proportion of patients showing each type of adverse event 
or any adverse event); (4) reduction in the usage of pain medication, the frequency of infection therapy, the need for physical therapy; and (5) the 
proportion of patients showing synovial thickening, joint effusion, meniscus tear, synovial enhancement, osteophytes. A point estimate and 95% 
confidence interval will be provided for each secondary outcome at each time and for the change in each outcome from baseline to each post-
treatment follow-up visit. Changes in the outcomes from baseline to follow-up will be tested using the paired-sample Wilcoxon signed rank test for 
the WOMAC and VAS scores and the McNemar test for the other measures which will be assessed as binary outcomes (e.g., whether or not the 
patient reported usage of pain medication on a daily basis).  
 
10.4.4 Safety Analyses
Safety endpoints will assess adverse event rate (defined as the proportion of patients showing each type of adverse event or any adverse event). 
The severity and causality of all adverse events will be graded according to the new adverse event classification by [CONTACT_772055] [30]. 
10.[ADDRESS_1059989] 80% power at the 5% significance level for testing the 
at will manifest a 
positive treatment response. As a result, the study will accrue [ADDRESS_1059990] with 80.4% power at a realized 
significance level of 0.047. with 20% attrition, the study will need 29 patients. We are requesting increase in the sample size to 40. With 20% with 
20% attrition, the study will need to enroll 50 patients. The PI [INVESTIGATOR_9814]-investigators determined that increase in the sample size is necessary to 
Study number: s19-[ZIP_CODE]   Page 44 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February 2020evaluate the role of GAE as a disease-modifying treatment option for knee OA. Since this current study is the only active study in the U.S 
collecting samples for biomarker analysis and the need for a larger sample size to evaluate changes in biomarker levels, an increase in sample 
size is needed.  
11 Source Documents and Access to Source Data/Documents
Source data is all information, original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction 
and evaluation of the trial.  Source data are contained in source documents.  Examples of these original documents, and data records include: 
hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, pharmacy dispensing records, 
recorded data from automated instruments, copi[INVESTIGATOR_10379], microfiches, 
photographic negatives, microfilm or magnetic media, x-rays, subject files, and records kept at the pharmacy, at the laboratories, and at medico-
technical departments involved in the clinical trial. It is acceptable to use CRFs as source documents. Data collected on electronic CRFs using 
TrialMaster are attached to this protocol (see attachment 4). 
 
The study case report form (CRF) is the primary data collection instrument for the study.  All data requested on the CRF must be recorded.  All 
missing data must be explained.  If a space on the CRF is left blank because the procedure was not done or the question was not asked, write 
“N/D”.  If the item is not applicable to the individual case, write “N/A”.  All entries should be printed legibly in black ink.  If any entry error has been 
made, to correct such an error, draw a single straight line through the incorrect entry and enter the correct data above it.  All such changes must 
be initialed and dated.  DO NOT ERASE OR WHITE OUT ERRORS.  For clarification of illegible or uncertain entries, print the clarification above 
the item, then initial and date it. 
 
Access to study records will be limited to IRB-approved members of the study team. The investigator will permit study-related monitoring, audits, 
and inspections by [CONTACT_1201]/EC, the sponsor, government regulatory bodies, and University compliance and quality assurance groups of all study 
related documents (e.g. source documents, regulatory documents, data collection instruments, study data etc.).  The investigator will ensure the 
capability for inspections of applicable study-related facilities (e.g. pharmacy, diagnostic laboratory, etc.). 
 
Participation as an investigator in this study implies acceptance of potential inspection by [CONTACT_226742]. 
 
12 Quality Assurance and Quality Control
QC procedures will be implemented beginning with the data entry system and data QC checks that will be run on the database will be generated. 
Any missing data or data anomalies will be communicated for clarification/resolution. 
 
The PI [INVESTIGATOR_457607], documented (recorded), and reported in compliance with the protocol, 
GCP, and the applicable regulatory requirements (e.g., Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP)). 
 
The investigational site will provide direct access to all trial related sites, source data/documents, and reports for the purpose of monitoring and 
auditing by [CONTACT_456], and inspection by [CONTACT_3482]. 
 
Study number: s19-[ZIP_CODE]   Page 45 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February 202013 Ethics/Protection of Human Subjects 
13.[ADDRESS_1059991]
All investigators will ensure that this study is conducted in full conformity with Regulations for the Protection of Human Subjects of Research 
codified in 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, and/or the ICH E6. 
 
13.[ADDRESS_1059992] 
The protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to the IRB for review and approval. 
Approval of both the protocol and the consent form must be obtained before any participant is enrolled. Any amendment to the protocol will require 
review and approval by [CONTACT_3484]. All changes to the consent form will be IRB approved; a 
determination will be made regarding whether previously consented participants need to be re-consented. 
13.3 Informed Consent Process
13.3.1 Consent/Assent and Other Informational Documents Provided to Participants 
Consent forms describing in detail the study agent, study procedures, and risks are given to the participant and written documentation of informed 
consent is required prior to starting intervention/administering study product. The consent form is submitted with this protocol (See attachment 9). 
 
13.3.2 Consent Procedures and Documentation 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study and continues throughout the individual’s 
study participation. Extensive discussion of risks and possible benefits of participation will be provided to the participants and their families. 
Consent forms will be IRB approved and the participant will be asked to read and review the document. The investigator will explain the research 
study to the participant and answer any questions that may arise. All participants will receive a verbal explanation in terms suited to their 
comprehension of the purposes, procedures, and potential risks of the study and of their rights as research participants. Participants will have the 
opportunity to carefully review the written consent form and ask questions prior to signing. The participants should have the opportunity to discuss 
the study with their surrogates or think about it prior to agreeing to participate. The participant will sign the informed consent document prior to any 
procedures being done specifically for the study. The participants may withdraw consent at any time throughout the course of the trial. A copy of 
the signed informed consent document will be given to the participants for their records. The rights and welfare of the participants will be protected 
by [CONTACT_34693]. 
 
A copy of the signed informed consent document will be stored in the subject’s research record. The consent process, including the name [CONTACT_671722], will be thoroughly documented in the subject’s research record. Any alteration to the standard consent process (e.g. 
use of a translator, consent from a legally authorized representative, consent document presented orally, etc.) and the justification for such 
alteration will likewise be documented.  
 
Study number: s19-[ZIP_CODE]   Page 46 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: [ADDRESS_1059993] of 1996 (HIPAA).  Those regulations require a signed subject authorization informing the subject of the following:  
 What protected health information (PHI) will be collected from subjects in this study 
 Who will have access to that information and why 
 Who will use or disclose that information  
 The rights of a research subject to revoke their authorization for use of their PHI.  
 
In the event that a subject revokes authorization to collect or use PHI, the investigator, by [CONTACT_5151], retains the ability to use all information 
collected prior to the revocation of subject authorization.  For subjects that have revoked authorization to collect or use PHI, attempts should be 
made to obtain permission to collect at least vital status (i.e. that the subject is alive) at the end of their scheduled study period. 
 
Participant confidentiality is strictly held in trust by [CONTACT_3486], their staff, and the sponsor(s) and their agents. This 
confidentiality is extended to cover testing of biological samples and genetic tests in addition to the clinical information relating to participants. 
Therefore, the study protocol, documentation, data, and all other information generated will be held in strict confidence. No information concerning 
the study or the data will be released to any unauthorized third party without prior written approval of the sponsor. 
 
The study monitor, other authorized representatives of the sponsor, representatives of the IRB or pharmaceutical company supplying study 
product may inspect all documents and records required to be maintained by [CONTACT_093], including but not limited to, medical records (office, 
clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. The clinical study site will permit access to such records. 
 
The study participant’s contact [CONTACT_10414]. At the end of the study, all 
records will continue to be kept in a secure location for as long a period as dictated by [CONTACT_46202]. 
 
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be transmitted to and stored at NYU 
Langone Health. This will not include the participant’s contact [CONTACT_1290]. Rather, individual participants and their research data will 
be identified by a unique study identification number. The study data entry and study management systems used by [CONTACT_772059]-approved, encrypted and HIPAA-compliant version of TrialMastermanaged by [CONTACT_553763]. At the end of the study, 
all study databases will be de-identified and archived at the NYU Langone Health. 
13.4.1 Research Use of Stored Human Samples, Specimens, or Data
Intended Use: data collected under this protocol may be used to study knee OA. No genetic testing will be performed.
 Storage: Access to stored samples will be limited to study personnel. Samples will be destroyed after the termination or completion of the 
study. . Data will be stored only on Trail Master and electronic medical records (EPIC). Data will be kept in password-protected computers. 
Only investigators will have access to the data. 
13.5 Future Use of Stored Specimens
Biospecimens collected for the study will not be stored for future research beyond the scope of the study 
Study number: s19-[ZIP_CODE]   Page 47 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: [ADDRESS_1059994] Keepi[INVESTIGATOR_007] 
14.1 Data Collection and Management Responsibilities
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site PI. The investigator is responsible for 
ensuring the accuracy, completeness, legibility, and timeliness of the data reported. 
 
All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data. Black ink is required to ensure 
clarity of reproduced copi[INVESTIGATOR_014]. When making changes or corrections, cross out the original entry with a single line, and initial and date the change. 
DO NOT ERASE, OVERWRITE, OR USE CORRECTION FLUID OR TAPE ON THE ORIGINAL. 
Copi[INVESTIGATOR_58625] (eCRF) will be provided for use as source documents and maintained for recording data for each participant enrolled 
in the study. Data reported in the eCRF derived from source documents should be consistent with the source documents or the discrepancies 
should be explained and captured in a progress note and maintained in the participant’s official electronic study record. 
 
Clinical data (including AEs, concomitant medications, and expected adverse reactions data) and clinical laboratory data will be entered into Trial 
Master internal, a [ADDRESS_1059995] protection and 
internal quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will be 
entered directly from the source documents. 
14.2 Study Records Retention
Study documents will be retained for the longer of 3 years after close-out, 5 years after final reporting/publication, or [ADDRESS_1059996] approval 
of a marketing application is approved for the device for the indication for which it is being investigated or 2 years after the investigation is 
discontinued and FDA is notified if no application is to be filed or if the application has not been approved for such indication. No records will be 
destroyed without the written consent of the sponsor, if applicable. It is the responsibility of the sponsor to inform the investigator when these 
documents no longer need to be retained. 
14.3 Protocol Deviations
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or Manual of Procedures (MOP) requirements. The noncompliance 
may be either on the part of the participant, the investigator, or the study site staff. As a result of deviations, corrective actions are to be developed 
by [CONTACT_3483]. 
 
These practices are consistent with ICH E6: 
 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3 
 5.1 Quality Assurance and Quality Control, section 5.1.1 
 5.20 Noncompliance, sections 5.20.1, and 5.20.2. 
 
It is the responsibility of the site PI/study staff to use continuous vigilance to identify and report deviations within [ADDRESS_1059997] be addressed in study source documents, reported to PI, IRB, and FDA 
Study number: s19-[ZIP_CODE]   Page 48 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: [ADDRESS_1059998] be reported to the local IRB per their guidelines. The site PI/study staff is responsible for knowing and adhering to their 
IRB requirements. Further details about the handling of protocol deviations will be included in the MOP. 
 
14.4 Publication and Data Sharing Policy
The International Committee of Medical Journal Editors (ICMJE) member journals have adopted a clinical trials registration policy as a condition 
for publication. The ICMJE defines a clinical trial as any research project that prospectively assigns human subjects to intervention or concurrent 
comparison or control groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Medical 
interventions include drugs, surgical procedures, devices, behavioral treatments, process-of-care changes, and the like. Health outcomes include 
any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. The 
ICMJE policy, and the Section [ADDRESS_1059999] of 2007, requires that all clinical trials be registered in a 
public trials registry such as ClinicalTrials.gov, which is sponsored by [CONTACT_1055]. Other biomedical journals are considering 
adopting similar policies. For interventional clinical trials performed under NIH IC grants and cooperative agreements, it is the grantee’s 
responsibility to register the trial in an acceptable registry, so the research results may be considered for publication in ICMJE member journals. 
The ICMJE does not review specific studies to determine whether registration is necessary; instead, the committee recommends that researchers 
who have questions about the need to register err on the side of registration or consult the editorial office of the journal in which they wish to 
publish. 
 
FDAAA mandates that a "responsible party" (i.e., the sponsor or designated principal investigator) register and report results of certain "applicable 
clinical trials": 
 
 Trials of Drugs and Biologics: Controlled, clinical investigations, other than Phase I investigations of a product subject to FDA regulation; 
 Trials of Devices: Controlled trials with health outcomes of a product subject to FDA regulation (other than small feasibility studies) and 
pediatric postmarket surveillance studies. 
 
[ADDRESS_1060000] to participants. 
 
Study number: s19-[ZIP_CODE]   Page 49 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: [ADDRESS_1060001] of the study. The Steering Committee will be composed of the PI [INVESTIGATOR_1238] a study co-investigator (A. 
Sista, MD). 
[ADDRESS_1060002] with this study (patent ownership, royalties, or financial gain greater than the minimum allowable by 
[CONTACT_1385], etc.) must have the conflict reviewed by [CONTACT_33913] (CIMU) with a Committee-
sanctioned conflict management plan that has been reviewed and approved by [CONTACT_28833]. All NYULMC 
investigators will follow the applicable conflict of interest policies. 
18 References 
1. Bijlsma JW, Berenbaum F, Lafeber FP: Osteoarthritis: an update with relevance for clinical practice.  Lancet 2011, 377:2115-2126. 
2. Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, Bridgett L, Williams S, Guillemin F, Hill CL, et al: The global burden of hip 
and knee osteoarthritis: estimates from the global burden of disease 2010 study.  Ann Rheum Dis 2014, 73:1323-1330. 
3. Peat G, McCarney R, Croft P: Knee pain and osteoarthritis in older adults: a review of community burden and current use of 
primary health care.  Annals of the rheumatic diseases 2001, 60:91-97. 
4. Blagojevic M, Jinks C, Jeffery A, Jordan KP: Risk factors for onset of osteoarthritis of the knee in older adults: a systematic review 
and meta-analysis.  Osteoarthritis Cartilage 2010, 18:24-33. 
5. Litwic A, Edwards MH, Dennison EM, Cooper C: Epi[INVESTIGATOR_772024].  Br Med Bull 2013, 105:185-199. 
6. Okuno Y, Korchi AM, Shinjo T, Kato S: Transcatheter arterial embolization as a treatment for medial knee pain in patients with mild 
to moderate osteoarthritis.  Cardiovascular and interventional radiology 2015, 38:336-343. 
7. McAlindon TE, Bannuru RR, Sullivan M, Arden N, Berenbaum F, Bierma-Zeinstra S, Hawker G, Henrotin Y, Hunter D, Kawaguchi H: 
OARSI guidelines for the non-surgical management of knee osteoarthritis.  Osteoarthritis and cartilage 2014, 22:363-388. 
Study number: s19-[ZIP_CODE]   Page 50 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: [ADDRESS_1060003] J, Croft P, Dixon J, Hurley M, Lohmander S, Raspe H: Knee replacement surgery for osteoarthritis: 
effectiveness, practice variations, indications and possible determinants of utilization.  Rheumatology (Oxford) 1999, 38:73-83. 
9. Dieppe P, Lim K, Lohmander S: Who should have knee joint replacement surgery for osteoarthritis?  International journal of 
rheumatic diseases 2011, 14:175-180. 
10. Mapp PI, Walsh DA: Mechanisms and targets of angiogenesis and nerve growth in osteoarthritis.  Nature Reviews Rheumatology 
2012, 8:390. 
11. Ashraf S, Mapp PI, Walsh DA: Contributions of angiogenesis to inflammation, joint damage, and pain in a rat model of 
osteoarthritis.  Arthritis & Rheumatism 2011, 63:2700-2710. 
12. Ashraf S, Wibberley H, Mapp PI, Hill R, Wilson D, Walsh DA: Increased vascular penetration and nerve growth in the meniscus: a 
potential source of pain in osteoarthritis.  Annals of the rheumatic diseases 2011, 70:523-529. 
13. Mapp P, Avery P, McWilliams D, Bowyer J, Day C, Moores S, Webster R, Walsh D: Angiogenesis in two animal models of 
osteoarthritis.  Osteoarthritis and cartilage 2008, 16:61-69. 
14. Suri S, Gill SE, de Camin SM, McWilliams DF, Wilson D, Walsh DA: Neurovascular invasion at the osteochondral junction and in 
osteophytes in osteoarthritis.  Annals of the rheumatic diseases 2007, 66:1423-1428. 
15. Walsh D, Bonnet C, Turner E, Wilson D, Situ M, McWilliams D: Angiogenesis in the synovium and at the osteochondral junction in 
osteoarthritis.  Osteoarthritis and cartilage 2007, 15:743-751. 
16. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW: Validation study of WOMAC: a health status instrument for 
measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip 
or knee.  The Journal of rheumatology 1988, 15:1833-1840. 
17. Peterfy C, Guermazi A, Zaim S, Tirman P, Miaux Y, White D, Kothari M, Lu Y, Fye K, Zhao S: Whole-organ magnetic resonance 
imaging score (WORMS) of the knee in osteoarthritis.  Osteoarthritis and Cartilage 2004, 12:177-190. 
18. Stampfl S, Bellemann N, Stampfl U, Radeleff B, Lopez-Benitez R, Sommer C-M, Thierjung H, Berger I, Richter GM: Inflammation and 
recanalization of four different spherical embolization agents in the porcine kidney model.  Journal of Vascular and Interventional 
Radiology 2008, 19:577-586. 
19. Stampfl S, Stampfl U, Bellemann N, Sommer CM, Thierjung H, Radeleff B, Lopez-Benitez R, Berger I, Kauffmann GW, Richter GM: 
Biocompatibility and recanalization characteristics of hydrogel microspheres with polyzene-F as polymer coating.  Cardiovascular 
and interventional radiology 2008, 31:799-806. 
20. Stampfl U, Radeleff B, Sommer C, Stampfl S, Dahlke A, Bellemann N, Kauczor H-U, Richter GM: Midterm results of uterine artery 
embolization using narrow-size calibrated embozene microspheres.  Cardiovascular and interventional radiology 2011, 34:295-305. 
21. Smeets AJ, Nijenhuis RJ, van Rooij WJ, Lampmann LE, Boekkooi PF, Vervest HA, De Vries J, Lohle PN: Embolization of uterine 
leiomyomas with polyzene F–coated hydrogel microspheres: Initial experience.  Journal of Vascular and Interventional Radiology 
2010, 21:1830-1834. 
22. Kalmar PI, Leithner A, Ehall R, Portugaller RH: Is embolization an effective treatment for recurrent hemorrhage after hip or knee 
arthroplasty?  Clinical Orthopaedics and Related Research® 2016, 474:267-271. 
23. Okuno Y, Korchi AM, Shinjo T, Kato S, Kaneko T: Midterm clinical outcomes and MR imaging changes after transcatheter arterial 
embolization as a treatment for mild to moderate radiographic knee osteoarthritis resistant to conservative treatment.  Journal of 
Vascular and Interventional Radiology 2017, 28:995-1002. 
24. Ayis S, Dieppe P: The natural history of disability and its determinants in adults with lower limb musculoskeletal pain.  The Journal 
of rheumatology 2009, 36:583-591. 
25. Dominick KL, Ahern FM, Gold CH, Heller DA: Health-related quality of life and health service use among older adults with 
osteoarthritis.  Arthritis Care & Research 2004, 51:326-331. 
Study number: s19-[ZIP_CODE]   Page 51 
Version: 06.25.2024   
CONFIDENTIAL 
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_625659]: 12 February 202026. Ikeda K, Nakagomi D, Sanayama Y, Yamagata M, Okubo A, Iwamoto T, Kawashima H, Takahashi K, Nakajima H: Correlation of 
radiographic progression with the cumulative activity of synovitis estimated by [CONTACT_772060]: difference between patients treated with methotrexate and those treated with biological agents.  The Journal of 
rheumatology 2013, 40:1967-1976. 
27. Pap T, Distler O: Linking angiogenesis to bone destruction in arthritis.  Arthritis & Rheumatism 2005, 52:1346-1348. 
28. Rabin R, Charro Fd: EQ-SD: a measure of health status from the EuroQol Group.  Annals of medicine 2001, 33:337-343. 
29. Riddle DL, Jiranek WA, Hull JR: Validity and reliability of radiographic knee osteoarthritis measures by [CONTACT_772061].  
Orthopedics 2013, 36:e25-e32. 
30. Khalilzadeh O, Baerlocher MO, Shyn PB, Connolly BL, Devane AM, Morris CS, Cohen AM, Midia M, Thornton RH, Gross K: Proposal of 
a new adverse event classification by [CONTACT_772062].  Journal of Vascular 
and Interventional Radiology 2017, 28:1432-1437. e1433. 
31.        Casella, G. (1986). Refining binomial confidence intervals. The Canadian Journal of Statistics, 14, 113--129.  
32.       Padia SA  et al. Genicular Artery Embolization for the Treatment of Symptomatic Knee Osteoarthritis. JB JS Open Access. [ADDRESS_1060004]-Dec; 6(4): 
e21.[ZIP_CODE].)  
 
 
 
19 Attachments
These documents are relevant to the protocol, but they are not considered part of the protocol.  They are stored and modified separately. As such, 
modifications to these documents do not require protocol amendments. 
 
Attachment 1_Embozene Derections for use (DFU) 
Attachment 2_Embozene FDA K180102 
Attachment 3_Embozene FDA_K141209 
Attachment 4_RedCap eCRF  
Attachment 5_Study Brochure 
Attachment 6_Recruitment sample subject direct email notification 
Attachment 7_Telephone Recruitment Script 
Attachment 8_FDA-3500A 
Attachment 9_IRB OA Consent_V0.1_07.08.2019 
 
 